Zeljković, Aleksandra

Link to this page

Authority KeyName Variants
orcid::0000-0001-6417-8404
  • Zeljković, Aleksandra (117)
Projects
Interactive role of dyslipidemia, oxidative stress and inflammation in atherosclerosis and other diseases: genetic and biochemical markers Ministry of Education, Science and Technological Development, Republic of Serbia, Grant no. 451-03-68/2020-14/200161 (University of Belgrade, Faculty of Pharmacy)
Ispitivanje biohemijskih i genetičkih faktora rizika kao uzročnika i markera ateroskleroze i drugih oboljenja: analitički i klinički aspekti HI-MOM - HIgh-density lipoprotein MetabolOMe research to improve pregnancy outcome
Antioxidative defense, differentiation and regeneration potential of tissue specific mesenchymal stem cells during ageing Ministry of Education, Science and Technological Development, Republic of Serbia, Grant no. 451-03-68/2020-14/200110 (University of Belgrade, Faculty of Medicine)
Ad Futura - Scientific and Educational Foundation of the Republic of Slovenia, by the Slovenian Research Agency grant P4-0127 and project BI-RS/12-13-048 Ad Futura - Scientific and Educational Foundation of the Republic of Slovenia, the Slovenian Research Agency, Republic of Slovenia grant P4-0127
APVV-0134-1 EU COST Action B35
Synthesis, Quantitative Structure and Activity Relationship, Physico-Chemical Characterisation and Analysis of Pharmacologically Active Substances Role of biomarkers in early detection of kidney injury and monitoring of therapy response in chidren
info:eu-repo/grantAgreement/MESTD/inst-2020/200043/RS/ Ministry of Education, Science and Technological Development, Republic of Serbia, Grant no. 451-03-68/2020-14/200043 (Institute of Oncology and Radiology of Serbia, Belgrade)
Studying climate change and its influence on environment: impacts, adaptation and mitigation Slovak Research and Development Agency of the Ministry of Education, Slovakia - VEGA 1/0863/15
The European Union—NextGenerationEU—MUR D.M. funds. 737/2021—research project entitled “Syndemic approach to cardiometabolic diseases during the COVID-19 era”. This investigation was financially supported by the Innovation Fund Republic of Serbia, Innovation vouchers Programme No. 152/2018
VEGA 1/0111/12, Slovakia

Author's Bibliography

HDL Subclasses and the Distribution of Paraoxonase-1 Activity in Patients with ST-Segment Elevation Acute Myocardial Infarction

Đekić, Saška; Vekić, Jelena; Zeljković, Aleksandra; Kotur-Stevuljević, Jelena; Kafedžić, Srđan; Zdravković, Marija; Ilić, Ivan; Hinić, Saša; Cerović, Milivoje; Stefanović, Milica; Mihajlović, Marija; Nešković, Aleksandar; Bogavac-Stanojević, Nataša

(MDPI, 2023)

TY  - JOUR
AU  - Đekić, Saška
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Kotur-Stevuljević, Jelena
AU  - Kafedžić, Srđan
AU  - Zdravković, Marija
AU  - Ilić, Ivan
AU  - Hinić, Saša
AU  - Cerović, Milivoje
AU  - Stefanović, Milica
AU  - Mihajlović, Marija
AU  - Nešković, Aleksandar
AU  - Bogavac-Stanojević, Nataša
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4843
AB  - The aim of this multicentric study was to assess the impacts of oxidative stress, inflam-
mation, and the presence of small, dense, low-density lipoproteins (sdLDL) on the antioxidative
function of high-density lipoprotein (HDL) subclasses and the distribution of paraoxonase-1 (PON1)
activity within HDL in patients with ST-segment elevation acute myocardial infarction (STEMI). In
69 STEMI patients and 67 healthy control subjects, the lipoproteins’ subclasses were separated using
polyacrylamide gradient (3–31%) gel electrophoresis. The relative proportion of sdLDL and each
HDL subclass was evaluated by measuring the areas under the peaks of densitometric scans. The
distribution of the relative proportion of PON1 activity within the HDL subclasses (pPON1 within
HDL) was estimated using the zymogram method. The STEMI patients had significantly lower
proportions of HDL2a and HDL3a subclasses (p = 0.001 and p < 0.001, respectively) and lower pPON1
within HDL3b (p = 0.006), as well as higher proportions of HDL3b and HDL3c subclasses (p = 0.013
and p < 0.001, respectively) and higher pPON1 within HDL2 than the controls. Independent positive
associations between sdLDL and pPON1 within HDL3a and between malondialdehyde (MDA) and
pPON1 within HDL2b were shown in the STEMI group. The increased oxidative stress and increased
proportion of sdLDL in STEMI are closely related to the compromised antioxidative function of small
HDL3 particles and the altered pPON1 within HDL.
PB  - MDPI
T2  - International Journal of Molecular Sciences
T1  - HDL Subclasses and the Distribution of Paraoxonase-1 Activity in Patients with ST-Segment Elevation Acute Myocardial Infarction
VL  - 24
IS  - 11
DO  - 10.3390/ijms24119384
ER  - 
@article{
author = "Đekić, Saška and Vekić, Jelena and Zeljković, Aleksandra and Kotur-Stevuljević, Jelena and Kafedžić, Srđan and Zdravković, Marija and Ilić, Ivan and Hinić, Saša and Cerović, Milivoje and Stefanović, Milica and Mihajlović, Marija and Nešković, Aleksandar and Bogavac-Stanojević, Nataša",
year = "2023",
abstract = "The aim of this multicentric study was to assess the impacts of oxidative stress, inflam-
mation, and the presence of small, dense, low-density lipoproteins (sdLDL) on the antioxidative
function of high-density lipoprotein (HDL) subclasses and the distribution of paraoxonase-1 (PON1)
activity within HDL in patients with ST-segment elevation acute myocardial infarction (STEMI). In
69 STEMI patients and 67 healthy control subjects, the lipoproteins’ subclasses were separated using
polyacrylamide gradient (3–31%) gel electrophoresis. The relative proportion of sdLDL and each
HDL subclass was evaluated by measuring the areas under the peaks of densitometric scans. The
distribution of the relative proportion of PON1 activity within the HDL subclasses (pPON1 within
HDL) was estimated using the zymogram method. The STEMI patients had significantly lower
proportions of HDL2a and HDL3a subclasses (p = 0.001 and p < 0.001, respectively) and lower pPON1
within HDL3b (p = 0.006), as well as higher proportions of HDL3b and HDL3c subclasses (p = 0.013
and p < 0.001, respectively) and higher pPON1 within HDL2 than the controls. Independent positive
associations between sdLDL and pPON1 within HDL3a and between malondialdehyde (MDA) and
pPON1 within HDL2b were shown in the STEMI group. The increased oxidative stress and increased
proportion of sdLDL in STEMI are closely related to the compromised antioxidative function of small
HDL3 particles and the altered pPON1 within HDL.",
publisher = "MDPI",
journal = "International Journal of Molecular Sciences",
title = "HDL Subclasses and the Distribution of Paraoxonase-1 Activity in Patients with ST-Segment Elevation Acute Myocardial Infarction",
volume = "24",
number = "11",
doi = "10.3390/ijms24119384"
}
Đekić, S., Vekić, J., Zeljković, A., Kotur-Stevuljević, J., Kafedžić, S., Zdravković, M., Ilić, I., Hinić, S., Cerović, M., Stefanović, M., Mihajlović, M., Nešković, A.,& Bogavac-Stanojević, N.. (2023). HDL Subclasses and the Distribution of Paraoxonase-1 Activity in Patients with ST-Segment Elevation Acute Myocardial Infarction. in International Journal of Molecular Sciences
MDPI., 24(11).
https://doi.org/10.3390/ijms24119384
Đekić S, Vekić J, Zeljković A, Kotur-Stevuljević J, Kafedžić S, Zdravković M, Ilić I, Hinić S, Cerović M, Stefanović M, Mihajlović M, Nešković A, Bogavac-Stanojević N. HDL Subclasses and the Distribution of Paraoxonase-1 Activity in Patients with ST-Segment Elevation Acute Myocardial Infarction. in International Journal of Molecular Sciences. 2023;24(11).
doi:10.3390/ijms24119384 .
Đekić, Saška, Vekić, Jelena, Zeljković, Aleksandra, Kotur-Stevuljević, Jelena, Kafedžić, Srđan, Zdravković, Marija, Ilić, Ivan, Hinić, Saša, Cerović, Milivoje, Stefanović, Milica, Mihajlović, Marija, Nešković, Aleksandar, Bogavac-Stanojević, Nataša, "HDL Subclasses and the Distribution of Paraoxonase-1 Activity in Patients with ST-Segment Elevation Acute Myocardial Infarction" in International Journal of Molecular Sciences, 24, no. 11 (2023),
https://doi.org/10.3390/ijms24119384 . .
1
4
1

Biochemical and hematological parameters in the 1 st trimester of pregnancy

Ivanišević, Jasmina; Ardalić, Daniela; Zeljković, Aleksandra; Vekić, Jelena; Gojković, Tamara; Vladimirov, Sandra; Antonić, Tamara; Munjas, Jelena; Stefanović, Aleksandra

(Savez farmaceutskih udruženja Srbije (SFUS), 2023)

TY  - JOUR
AU  - Ivanišević, Jasmina
AU  - Ardalić, Daniela
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Gojković, Tamara
AU  - Vladimirov, Sandra
AU  - Antonić, Tamara
AU  - Munjas, Jelena
AU  - Stefanović, Aleksandra
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4637
AB  - The 1st trimester of pregnancy is accompanied with changes in different biochemical and
hematological parameters. Analyses scheduled to be performed in the 1st trimester are complete
blood count, blood group, Rh factor and the double test. Many experts also suggest the
determination of lipid status parameters as a routine analysis in the early pregnancy. Reliable data
about maternal and fetal health can be obtained by the assessment of the above-mentioned
parameters. They may be helpful in assessing the risk for pregnancy complication development
and/or perinatal adverse outcomes.
AB  - Prvi trimestar trudnoće praćen je promenama različitih biohemijskih i hematoloških
parametara. Analize koje se rade u 1. trimestru su kompletna krvna slika, krvna grupa, Rh faktor
i tzv. „double“ test. Mnogi stručnjaci predlažu određivanje parametara lipidnog statusa kao
rutinsku analizu u ranoj trudnoći. Procenom gore navedenih parametara mogu se dobiti pouzdani
podaci o zdravlju majke i fetusa, a mogu da posluže i za procenu rizika za razvoj komplikacija u
trudnoći i/ili perinatalnih neželjenih ishoda.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
T2  - Arhiv za farmaciju
T1  - Biochemical and hematological parameters in the  1 st  trimester of pregnancy
T1  - Biohemijski i hematološki parametri u prvom  trimestru trudnoće
VL  - 73
IS  - 1
SP  - 62
EP  - 73
DO  - 10.5937/arhfarm73-41999
ER  - 
@article{
author = "Ivanišević, Jasmina and Ardalić, Daniela and Zeljković, Aleksandra and Vekić, Jelena and Gojković, Tamara and Vladimirov, Sandra and Antonić, Tamara and Munjas, Jelena and Stefanović, Aleksandra",
year = "2023",
abstract = "The 1st trimester of pregnancy is accompanied with changes in different biochemical and
hematological parameters. Analyses scheduled to be performed in the 1st trimester are complete
blood count, blood group, Rh factor and the double test. Many experts also suggest the
determination of lipid status parameters as a routine analysis in the early pregnancy. Reliable data
about maternal and fetal health can be obtained by the assessment of the above-mentioned
parameters. They may be helpful in assessing the risk for pregnancy complication development
and/or perinatal adverse outcomes., Prvi trimestar trudnoće praćen je promenama različitih biohemijskih i hematoloških
parametara. Analize koje se rade u 1. trimestru su kompletna krvna slika, krvna grupa, Rh faktor
i tzv. „double“ test. Mnogi stručnjaci predlažu određivanje parametara lipidnog statusa kao
rutinsku analizu u ranoj trudnoći. Procenom gore navedenih parametara mogu se dobiti pouzdani
podaci o zdravlju majke i fetusa, a mogu da posluže i za procenu rizika za razvoj komplikacija u
trudnoći i/ili perinatalnih neželjenih ishoda.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Biochemical and hematological parameters in the  1 st  trimester of pregnancy, Biohemijski i hematološki parametri u prvom  trimestru trudnoće",
volume = "73",
number = "1",
pages = "62-73",
doi = "10.5937/arhfarm73-41999"
}
Ivanišević, J., Ardalić, D., Zeljković, A., Vekić, J., Gojković, T., Vladimirov, S., Antonić, T., Munjas, J.,& Stefanović, A.. (2023). Biochemical and hematological parameters in the  1 st  trimester of pregnancy. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 73(1), 62-73.
https://doi.org/10.5937/arhfarm73-41999
Ivanišević J, Ardalić D, Zeljković A, Vekić J, Gojković T, Vladimirov S, Antonić T, Munjas J, Stefanović A. Biochemical and hematological parameters in the  1 st  trimester of pregnancy. in Arhiv za farmaciju. 2023;73(1):62-73.
doi:10.5937/arhfarm73-41999 .
Ivanišević, Jasmina, Ardalić, Daniela, Zeljković, Aleksandra, Vekić, Jelena, Gojković, Tamara, Vladimirov, Sandra, Antonić, Tamara, Munjas, Jelena, Stefanović, Aleksandra, "Biochemical and hematological parameters in the  1 st  trimester of pregnancy" in Arhiv za farmaciju, 73, no. 1 (2023):62-73,
https://doi.org/10.5937/arhfarm73-41999 . .

Cholesterol Metabolic Profiling of HDL in Women with Late-Onset Preeclampsia

Antonić, Tamara; Ardalić, Daniela; Vladimirov, Sandra; Zeljković, Aleksandra; Vekić, Jelena; Mitrović, Marija; Ivanišević, Jasmina; Gojković, Tamara; Munjas, Jelena; Spasojević-Kalimanovska, Vesna; Miković, Željko; Stefanović, Aleksandra

(MDPI, 2023)

TY  - JOUR
AU  - Antonić, Tamara
AU  - Ardalić, Daniela
AU  - Vladimirov, Sandra
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Mitrović, Marija
AU  - Ivanišević, Jasmina
AU  - Gojković, Tamara
AU  - Munjas, Jelena
AU  - Spasojević-Kalimanovska, Vesna
AU  - Miković, Željko
AU  - Stefanović, Aleksandra
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4957
AB  - A specific feature of dyslipidemia in pregnancy is increased high-density lipoprotein (HDL) cholesterol concentration, which is probably associated with maternal endothelium protection. However, preeclampsia is most often associated with low HDL cholesterol, and the mechanisms behind this change are scarcely explored. We aimed to investigate changes in HDL metabolism in risky pregnancies and those complicated by late-onset preeclampsia. We analyze cholesterol synthesis (cholesterol precursors: desmosterol, 7-dehydrocholesterol, and lathosterol) and absorption markers (phytosterols: campesterol and β-sitosterol) within HDL particles (NCSHDL), the activities of principal modulators of HDL cholesterol’s content, and major HDL functional proteins levels in mid and late pregnancy. On the basis of the pregnancy outcome, participants were classified into the risk group (RG) (70 women) and the preeclampsia group (PG) (20 women). HDL cholesterol was lower in PG in the second trimester compared to RG (p < 0.05) and followed by lower levels of cholesterol absorption markers (p < 0.001 for campesterolHDL and p < 0.05 for β-sitosterolHDL). Lowering of HDL cholesterol between trimesters in RG (p < 0.05) was accompanied by a decrease in HDL phytosterol content (p < 0.001), apolipoprotein A-I (apoA-I) concentration (p < 0.05), and paraoxonase 1 (PON1) (p < 0.001), lecithin–cholesterol acyltransferase (LCAT) (p < 0.05), and cholesterol ester transfer protein (CETP) activities (p < 0.05). These longitudinal changes were absent in PG. Development of late-onset preeclampsia is preceded by the appearance of lower HDL cholesterol and NCSHDL in the second trimester. We propose that reduced capacity for intestinal HDL synthesis, decreased LCAT activity, and impaired capacity for HDL-mediated cholesterol efflux could be the contributing mechanisms resulting in lower HDL cholesterol.
PB  - MDPI
T2  - International Journal of Molecular Sciences
T1  - Cholesterol Metabolic Profiling of HDL in Women with Late-Onset Preeclampsia
VL  - 24
IS  - 14
DO  - 10.3390/ijms241411357
ER  - 
@article{
author = "Antonić, Tamara and Ardalić, Daniela and Vladimirov, Sandra and Zeljković, Aleksandra and Vekić, Jelena and Mitrović, Marija and Ivanišević, Jasmina and Gojković, Tamara and Munjas, Jelena and Spasojević-Kalimanovska, Vesna and Miković, Željko and Stefanović, Aleksandra",
year = "2023",
abstract = "A specific feature of dyslipidemia in pregnancy is increased high-density lipoprotein (HDL) cholesterol concentration, which is probably associated with maternal endothelium protection. However, preeclampsia is most often associated with low HDL cholesterol, and the mechanisms behind this change are scarcely explored. We aimed to investigate changes in HDL metabolism in risky pregnancies and those complicated by late-onset preeclampsia. We analyze cholesterol synthesis (cholesterol precursors: desmosterol, 7-dehydrocholesterol, and lathosterol) and absorption markers (phytosterols: campesterol and β-sitosterol) within HDL particles (NCSHDL), the activities of principal modulators of HDL cholesterol’s content, and major HDL functional proteins levels in mid and late pregnancy. On the basis of the pregnancy outcome, participants were classified into the risk group (RG) (70 women) and the preeclampsia group (PG) (20 women). HDL cholesterol was lower in PG in the second trimester compared to RG (p < 0.05) and followed by lower levels of cholesterol absorption markers (p < 0.001 for campesterolHDL and p < 0.05 for β-sitosterolHDL). Lowering of HDL cholesterol between trimesters in RG (p < 0.05) was accompanied by a decrease in HDL phytosterol content (p < 0.001), apolipoprotein A-I (apoA-I) concentration (p < 0.05), and paraoxonase 1 (PON1) (p < 0.001), lecithin–cholesterol acyltransferase (LCAT) (p < 0.05), and cholesterol ester transfer protein (CETP) activities (p < 0.05). These longitudinal changes were absent in PG. Development of late-onset preeclampsia is preceded by the appearance of lower HDL cholesterol and NCSHDL in the second trimester. We propose that reduced capacity for intestinal HDL synthesis, decreased LCAT activity, and impaired capacity for HDL-mediated cholesterol efflux could be the contributing mechanisms resulting in lower HDL cholesterol.",
publisher = "MDPI",
journal = "International Journal of Molecular Sciences",
title = "Cholesterol Metabolic Profiling of HDL in Women with Late-Onset Preeclampsia",
volume = "24",
number = "14",
doi = "10.3390/ijms241411357"
}
Antonić, T., Ardalić, D., Vladimirov, S., Zeljković, A., Vekić, J., Mitrović, M., Ivanišević, J., Gojković, T., Munjas, J., Spasojević-Kalimanovska, V., Miković, Ž.,& Stefanović, A.. (2023). Cholesterol Metabolic Profiling of HDL in Women with Late-Onset Preeclampsia. in International Journal of Molecular Sciences
MDPI., 24(14).
https://doi.org/10.3390/ijms241411357
Antonić T, Ardalić D, Vladimirov S, Zeljković A, Vekić J, Mitrović M, Ivanišević J, Gojković T, Munjas J, Spasojević-Kalimanovska V, Miković Ž, Stefanović A. Cholesterol Metabolic Profiling of HDL in Women with Late-Onset Preeclampsia. in International Journal of Molecular Sciences. 2023;24(14).
doi:10.3390/ijms241411357 .
Antonić, Tamara, Ardalić, Daniela, Vladimirov, Sandra, Zeljković, Aleksandra, Vekić, Jelena, Mitrović, Marija, Ivanišević, Jasmina, Gojković, Tamara, Munjas, Jelena, Spasojević-Kalimanovska, Vesna, Miković, Željko, Stefanović, Aleksandra, "Cholesterol Metabolic Profiling of HDL in Women with Late-Onset Preeclampsia" in International Journal of Molecular Sciences, 24, no. 14 (2023),
https://doi.org/10.3390/ijms241411357 . .
1
1

Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk

Vekić, Jelena; Stromsnes, Kristine; Mazzalai, Stefania; Zeljković, Aleksandra; Rizzo, Manfredi; Gambini, Juan

(MDPI, 2023)

TY  - JOUR
AU  - Vekić, Jelena
AU  - Stromsnes, Kristine
AU  - Mazzalai, Stefania
AU  - Zeljković, Aleksandra
AU  - Rizzo, Manfredi
AU  - Gambini, Juan
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5340
AB  - Oxidative stress is the consequence of an overproduction of reactive oxygen species (ROS) that exceeds the antioxidant defense mechanisms. Increased levels of ROS contribute to the development of cardiovascular disorders through oxidative damage to macromolecules, particularly by oxidation of plasma lipoproteins. One of the most prominent features of atherogenic dyslipidemia is plasma accumulation of small dense LDL (sdLDL) particles, characterized by an increased susceptibility to oxidation. Indeed, a considerable and diverse body of evidence from animal models and epidemiological studies was generated supporting oxidative modification of sdLDL particles as the earliest event in atherogenesis. Lipid peroxidation of LDL particles results in the formation of various bioactive species that contribute to the atherosclerotic process through different pathophysiological mechanisms, including foam cell formation, direct detrimental effects, and receptor-mediated activation of pro-inflammatory signaling pathways. In this paper, we will discuss recent data on the pathophysiological role of oxidative stress and atherogenic dyslipidemia and their interplay in the development of atherosclerosis. In addition, a special focus will be placed on the clinical applicability of novel, promising biomarkers of these processes.
PB  - MDPI
T2  - Biomedicines
T1  - Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk
VL  - 11
IS  - 11
DO  - 10.3390/biomedicines11112897
ER  - 
@article{
author = "Vekić, Jelena and Stromsnes, Kristine and Mazzalai, Stefania and Zeljković, Aleksandra and Rizzo, Manfredi and Gambini, Juan",
year = "2023",
abstract = "Oxidative stress is the consequence of an overproduction of reactive oxygen species (ROS) that exceeds the antioxidant defense mechanisms. Increased levels of ROS contribute to the development of cardiovascular disorders through oxidative damage to macromolecules, particularly by oxidation of plasma lipoproteins. One of the most prominent features of atherogenic dyslipidemia is plasma accumulation of small dense LDL (sdLDL) particles, characterized by an increased susceptibility to oxidation. Indeed, a considerable and diverse body of evidence from animal models and epidemiological studies was generated supporting oxidative modification of sdLDL particles as the earliest event in atherogenesis. Lipid peroxidation of LDL particles results in the formation of various bioactive species that contribute to the atherosclerotic process through different pathophysiological mechanisms, including foam cell formation, direct detrimental effects, and receptor-mediated activation of pro-inflammatory signaling pathways. In this paper, we will discuss recent data on the pathophysiological role of oxidative stress and atherogenic dyslipidemia and their interplay in the development of atherosclerosis. In addition, a special focus will be placed on the clinical applicability of novel, promising biomarkers of these processes.",
publisher = "MDPI",
journal = "Biomedicines",
title = "Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk",
volume = "11",
number = "11",
doi = "10.3390/biomedicines11112897"
}
Vekić, J., Stromsnes, K., Mazzalai, S., Zeljković, A., Rizzo, M.,& Gambini, J.. (2023). Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk. in Biomedicines
MDPI., 11(11).
https://doi.org/10.3390/biomedicines11112897
Vekić J, Stromsnes K, Mazzalai S, Zeljković A, Rizzo M, Gambini J. Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk. in Biomedicines. 2023;11(11).
doi:10.3390/biomedicines11112897 .
Vekić, Jelena, Stromsnes, Kristine, Mazzalai, Stefania, Zeljković, Aleksandra, Rizzo, Manfredi, Gambini, Juan, "Oxidative Stress, Atherogenic Dyslipidemia, and Cardiovascular Risk" in Biomedicines, 11, no. 11 (2023),
https://doi.org/10.3390/biomedicines11112897 . .

The Role of Advanced Glycation End Products on Dyslipidemia

Vekić, Jelena; Vujčić, Sanja; Bufan, Biljana; Bojanin, Dragana; Al-Hashmi, Khamis; Al-Rasadi, Khaild; Stoian, Anca Pantea; Zeljković, Aleksandra; Rizzo, Manfredi

(MDPI, 2023)

TY  - JOUR
AU  - Vekić, Jelena
AU  - Vujčić, Sanja
AU  - Bufan, Biljana
AU  - Bojanin, Dragana
AU  - Al-Hashmi, Khamis
AU  - Al-Rasadi, Khaild
AU  - Stoian, Anca Pantea
AU  - Zeljković, Aleksandra
AU  - Rizzo, Manfredi
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4415
AB  - Disorders of lipoprotein metabolism and glucose homeostasis are common consequences of insulin resistance and usually co-segregate in patients with metabolic syndrome and type 2 diabetes mellitus (DM). Insulin-resistant subjects are characterized by atherogenic dyslipidemia, a specific lipid pattern which includes hypertriglyceridemia, reduced high-density lipoprotein cholesterol level, and increased proportion of small, dense low-density lipoprotein (LDL). Chronic hyperglycemia favors the processes of non-enzymatic glycation, leading to the increased production of advanced glycation end products (AGEs). Apart from direct harmful effects, AGEs are also potent inducers of oxidative stress and inflammation. In addition, increased AGEs’ production may induce further qualitative modifications of small, dense LDL particles, converting them to glycated LDLs. These particles are even more atherogenic and may confer an increased cardiovascular risk. In this narrative review, we summarize the available evidence of the pathophysiological role and clinical importance of circulating AGEs and glycated LDLs in patients with dyslipidemia, particularly those with DM and related complications. In addition, we discuss recent advances and the issues that should be improved regarding laboratory assessment of AGEs and glycated LDLs, as well as the possibilities for their therapeutic modulation.
PB  - MDPI
T2  - Metabolites
T1  - The Role of Advanced Glycation End Products on Dyslipidemia
VL  - 13
IS  - 1
DO  - 10.3390/metabo13010077
ER  - 
@article{
author = "Vekić, Jelena and Vujčić, Sanja and Bufan, Biljana and Bojanin, Dragana and Al-Hashmi, Khamis and Al-Rasadi, Khaild and Stoian, Anca Pantea and Zeljković, Aleksandra and Rizzo, Manfredi",
year = "2023",
abstract = "Disorders of lipoprotein metabolism and glucose homeostasis are common consequences of insulin resistance and usually co-segregate in patients with metabolic syndrome and type 2 diabetes mellitus (DM). Insulin-resistant subjects are characterized by atherogenic dyslipidemia, a specific lipid pattern which includes hypertriglyceridemia, reduced high-density lipoprotein cholesterol level, and increased proportion of small, dense low-density lipoprotein (LDL). Chronic hyperglycemia favors the processes of non-enzymatic glycation, leading to the increased production of advanced glycation end products (AGEs). Apart from direct harmful effects, AGEs are also potent inducers of oxidative stress and inflammation. In addition, increased AGEs’ production may induce further qualitative modifications of small, dense LDL particles, converting them to glycated LDLs. These particles are even more atherogenic and may confer an increased cardiovascular risk. In this narrative review, we summarize the available evidence of the pathophysiological role and clinical importance of circulating AGEs and glycated LDLs in patients with dyslipidemia, particularly those with DM and related complications. In addition, we discuss recent advances and the issues that should be improved regarding laboratory assessment of AGEs and glycated LDLs, as well as the possibilities for their therapeutic modulation.",
publisher = "MDPI",
journal = "Metabolites",
title = "The Role of Advanced Glycation End Products on Dyslipidemia",
volume = "13",
number = "1",
doi = "10.3390/metabo13010077"
}
Vekić, J., Vujčić, S., Bufan, B., Bojanin, D., Al-Hashmi, K., Al-Rasadi, K., Stoian, A. P., Zeljković, A.,& Rizzo, M.. (2023). The Role of Advanced Glycation End Products on Dyslipidemia. in Metabolites
MDPI., 13(1).
https://doi.org/10.3390/metabo13010077
Vekić J, Vujčić S, Bufan B, Bojanin D, Al-Hashmi K, Al-Rasadi K, Stoian AP, Zeljković A, Rizzo M. The Role of Advanced Glycation End Products on Dyslipidemia. in Metabolites. 2023;13(1).
doi:10.3390/metabo13010077 .
Vekić, Jelena, Vujčić, Sanja, Bufan, Biljana, Bojanin, Dragana, Al-Hashmi, Khamis, Al-Rasadi, Khaild, Stoian, Anca Pantea, Zeljković, Aleksandra, Rizzo, Manfredi, "The Role of Advanced Glycation End Products on Dyslipidemia" in Metabolites, 13, no. 1 (2023),
https://doi.org/10.3390/metabo13010077 . .
1
7
6

Metabolic and inflammatory homeostasis disorders in the pathogenesis of colorectal cancer

Mihajlović, Marija; Ninić, Ana; Ostojić, Marija; Sopić, Miron; Stefanović, Aleksandra; Vekić, Jelena; Antonić, Tamara; Spasojević-Kalimanovska, Vesna; Bogavac-Stanojević, Nataša; Zeljković, Aleksandra

(Savez farmaceutskih udruženja Srbije (SFUS), 2022)

TY  - CONF
AU  - Mihajlović, Marija
AU  - Ninić, Ana
AU  - Ostojić, Marija
AU  - Sopić, Miron
AU  - Stefanović, Aleksandra
AU  - Vekić, Jelena
AU  - Antonić, Tamara
AU  - Spasojević-Kalimanovska, Vesna
AU  - Bogavac-Stanojević, Nataša
AU  - Zeljković, Aleksandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4645
AB  - In order to understand the metabolic and immune potential of adiponectin in
colorectal cancer (CRC), attention is drawn to its receptors: adiponectin receptor 1
(ADIPOR1) and adiponectin receptor 2 (ADIPOR2). Gene set enrichment analysis (GSEA) of
datasets based on malignant tissue samples and peripheral blood monocytes (PBMs) was
used to explore mRNA fingerprints of different signaling pathways best associated with
ADIPOR1/ADIPOR2 gene expression levels. Transcriptomic datasets GSE44076 (1) and
GSE47756 (2) were downloaded from the NCBI Gene Expression Omnibus database. In the
GSE44076 dataset, three groups were formed: 98 colon tumor tissue and matched tumor-
adjacent mucosa samples and tissue samples from 50 healthy volunteers. The other set
(GSE47756) contained information on PBMs' gene signature in CRC, by forming two groups:
38 samples from healthy subjects and 55 CRC patients. GSEA analysis of the GSE44076
dataset implied that ADIPOR1 mRNA levels were in negative association with MTORC1 and
TNF-α NF-κB signaling pathways in tumor tissue. At the same time, ADIPOR2 was positively
associated with metabolic gene sets such as cholesterol homeostasis, glycolysis and PPAR
signaling. Quite opposite to the GSE44076 dataset, GSEA analysisis of GSE47756 revealed
that ADIPOR1 was a metabolically active receptor in PBMs of CRC patients. Surprisingly, the
TNF-α NF-κB signaling pathway gene sets were positively associated with ADIPOR1 mRNA
levels in monocytes of the cancer group. Different types of metabolic and immune regulation
achieved through ADIPOR1/ADIPOR2 in tumor and PBMs suggest possible novel therapeutic
targets in CRC.
AB  - Da bi se razumeo metabolički i imuni potencijal adiponektina u kolorektalnom
karcinomu (CRC), pažnja se mora obratiti i na njegove receptore: adiponektinski receptor 1
(ADIPOR1) i adiponektinski receptor 2 (ADIPOR2). Gene set enrichment analiza (GSEA) dva
skupa podataka, zasnovanih na uzorcima malignog tkiva i na monocitima periferne krvi
(PBM) je korišćena da bi se obezbedili genetski otisci različitih signalnih puteva koji su bili
najbolje povezani sa ekspresijom gena ADIPOR1/ADIPOR2. Skupovi transkriptomskih
podataka GSE44076 (1) i GSE47756 (2) su preuzeti iz NCBI Gene Expression Omnibus baze
podataka. U skupu podataka GSE44076 formirane su tri grupe: 98 uparenih uzoraka
tumorskog tkiva debelog creva i susedne mukoze i uzorci tkiva 50 zdravih dobrovoljaca.
Drugi set (GSE47756) je sadržao informacije o otisku gena PBM u CRC sa formiranim dvema
grupama: 38 uzoraka zdravih subjekata i 55 pacijenata sa CRC. GSEA analiza skupa podataka
GSE44076 je implicira da su nivoi iRNK ADIPOR1 negativno korelirali sa MTORC1 i TNF-α
NF-κB signalnim putevima u tumorskom tkivu. Istovremeno, ADIPOR2 je bio pozitivno
povezan sa skupovima gena metaboličkih puteva kao što su homeostaza holesterola,
glikoliza i PPAR signalizacija. Nasuprot GSE44076 skupu podataka, GSEA analiza GSE47756
transkriptomskog seta je otkrila da je ADIPOR1 zapravo metabolički aktivan receptor u PBM
pacijenata sa CRC. Iznenađujuć e, setovi gena koji su se odnosili na signalni put TNF-α NF-κB
su bili pozitivno povezani sa nivoima iRNK ADIPOR1 u monocitima grupe sa karcinomom.
Različite vrste metaboličke i imune regulacije koje se postižu preko ADIPOR1/ADIPOR2 u
tumoru i PBM sugerišu moguć e nove terapeutske ciljeve u CRC.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Metabolic and inflammatory homeostasis disorders in the pathogenesis of colorectal cancer
T1  - Poremećaji metaboličke i inflamatorne homeostaze u patogenezi kolorektalnog karcinoma
VL  - 72
IS  - 4 suplement
SP  - S622
EP  - S623
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4645
ER  - 
@conference{
author = "Mihajlović, Marija and Ninić, Ana and Ostojić, Marija and Sopić, Miron and Stefanović, Aleksandra and Vekić, Jelena and Antonić, Tamara and Spasojević-Kalimanovska, Vesna and Bogavac-Stanojević, Nataša and Zeljković, Aleksandra",
year = "2022",
abstract = "In order to understand the metabolic and immune potential of adiponectin in
colorectal cancer (CRC), attention is drawn to its receptors: adiponectin receptor 1
(ADIPOR1) and adiponectin receptor 2 (ADIPOR2). Gene set enrichment analysis (GSEA) of
datasets based on malignant tissue samples and peripheral blood monocytes (PBMs) was
used to explore mRNA fingerprints of different signaling pathways best associated with
ADIPOR1/ADIPOR2 gene expression levels. Transcriptomic datasets GSE44076 (1) and
GSE47756 (2) were downloaded from the NCBI Gene Expression Omnibus database. In the
GSE44076 dataset, three groups were formed: 98 colon tumor tissue and matched tumor-
adjacent mucosa samples and tissue samples from 50 healthy volunteers. The other set
(GSE47756) contained information on PBMs' gene signature in CRC, by forming two groups:
38 samples from healthy subjects and 55 CRC patients. GSEA analysis of the GSE44076
dataset implied that ADIPOR1 mRNA levels were in negative association with MTORC1 and
TNF-α NF-κB signaling pathways in tumor tissue. At the same time, ADIPOR2 was positively
associated with metabolic gene sets such as cholesterol homeostasis, glycolysis and PPAR
signaling. Quite opposite to the GSE44076 dataset, GSEA analysisis of GSE47756 revealed
that ADIPOR1 was a metabolically active receptor in PBMs of CRC patients. Surprisingly, the
TNF-α NF-κB signaling pathway gene sets were positively associated with ADIPOR1 mRNA
levels in monocytes of the cancer group. Different types of metabolic and immune regulation
achieved through ADIPOR1/ADIPOR2 in tumor and PBMs suggest possible novel therapeutic
targets in CRC., Da bi se razumeo metabolički i imuni potencijal adiponektina u kolorektalnom
karcinomu (CRC), pažnja se mora obratiti i na njegove receptore: adiponektinski receptor 1
(ADIPOR1) i adiponektinski receptor 2 (ADIPOR2). Gene set enrichment analiza (GSEA) dva
skupa podataka, zasnovanih na uzorcima malignog tkiva i na monocitima periferne krvi
(PBM) je korišćena da bi se obezbedili genetski otisci različitih signalnih puteva koji su bili
najbolje povezani sa ekspresijom gena ADIPOR1/ADIPOR2. Skupovi transkriptomskih
podataka GSE44076 (1) i GSE47756 (2) su preuzeti iz NCBI Gene Expression Omnibus baze
podataka. U skupu podataka GSE44076 formirane su tri grupe: 98 uparenih uzoraka
tumorskog tkiva debelog creva i susedne mukoze i uzorci tkiva 50 zdravih dobrovoljaca.
Drugi set (GSE47756) je sadržao informacije o otisku gena PBM u CRC sa formiranim dvema
grupama: 38 uzoraka zdravih subjekata i 55 pacijenata sa CRC. GSEA analiza skupa podataka
GSE44076 je implicira da su nivoi iRNK ADIPOR1 negativno korelirali sa MTORC1 i TNF-α
NF-κB signalnim putevima u tumorskom tkivu. Istovremeno, ADIPOR2 je bio pozitivno
povezan sa skupovima gena metaboličkih puteva kao što su homeostaza holesterola,
glikoliza i PPAR signalizacija. Nasuprot GSE44076 skupu podataka, GSEA analiza GSE47756
transkriptomskog seta je otkrila da je ADIPOR1 zapravo metabolički aktivan receptor u PBM
pacijenata sa CRC. Iznenađujuć e, setovi gena koji su se odnosili na signalni put TNF-α NF-κB
su bili pozitivno povezani sa nivoima iRNK ADIPOR1 u monocitima grupe sa karcinomom.
Različite vrste metaboličke i imune regulacije koje se postižu preko ADIPOR1/ADIPOR2 u
tumoru i PBM sugerišu moguć e nove terapeutske ciljeve u CRC.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Metabolic and inflammatory homeostasis disorders in the pathogenesis of colorectal cancer, Poremećaji metaboličke i inflamatorne homeostaze u patogenezi kolorektalnog karcinoma",
volume = "72",
number = "4 suplement",
pages = "S622-S623",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4645"
}
Mihajlović, M., Ninić, A., Ostojić, M., Sopić, M., Stefanović, A., Vekić, J., Antonić, T., Spasojević-Kalimanovska, V., Bogavac-Stanojević, N.,& Zeljković, A.. (2022). Metabolic and inflammatory homeostasis disorders in the pathogenesis of colorectal cancer. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S622-S623.
https://hdl.handle.net/21.15107/rcub_farfar_4645
Mihajlović M, Ninić A, Ostojić M, Sopić M, Stefanović A, Vekić J, Antonić T, Spasojević-Kalimanovska V, Bogavac-Stanojević N, Zeljković A. Metabolic and inflammatory homeostasis disorders in the pathogenesis of colorectal cancer. in Arhiv za farmaciju. 2022;72(4 suplement):S622-S623.
https://hdl.handle.net/21.15107/rcub_farfar_4645 .
Mihajlović, Marija, Ninić, Ana, Ostojić, Marija, Sopić, Miron, Stefanović, Aleksandra, Vekić, Jelena, Antonić, Tamara, Spasojević-Kalimanovska, Vesna, Bogavac-Stanojević, Nataša, Zeljković, Aleksandra, "Metabolic and inflammatory homeostasis disorders in the pathogenesis of colorectal cancer" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S622-S623,
https://hdl.handle.net/21.15107/rcub_farfar_4645 .

Association between cholesterol synthesis markers and biological sex in the healthy, middle-aged population

Vladimirov, Sandra; Gojković, Tamara; Zeljković, Aleksandra; Bogavac-Stanojević, Nataša; Spasojević-Kalimanovska, Vesna

(Elsevier Inc., 2022)

TY  - CONF
AU  - Vladimirov, Sandra
AU  - Gojković, Tamara
AU  - Zeljković, Aleksandra
AU  - Bogavac-Stanojević, Nataša
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4359
PB  - Elsevier Inc.
C3  - Atherosclerosis
T1  - Association between cholesterol synthesis markers and biological sex in the healthy, middle-aged population
VL  - 355
SP  - E238
EP  - E238
DO  - 10.1016/j.atherosclerosis.2022.06.677
ER  - 
@conference{
author = "Vladimirov, Sandra and Gojković, Tamara and Zeljković, Aleksandra and Bogavac-Stanojević, Nataša and Spasojević-Kalimanovska, Vesna",
year = "2022",
publisher = "Elsevier Inc.",
journal = "Atherosclerosis",
title = "Association between cholesterol synthesis markers and biological sex in the healthy, middle-aged population",
volume = "355",
pages = "E238-E238",
doi = "10.1016/j.atherosclerosis.2022.06.677"
}
Vladimirov, S., Gojković, T., Zeljković, A., Bogavac-Stanojević, N.,& Spasojević-Kalimanovska, V.. (2022). Association between cholesterol synthesis markers and biological sex in the healthy, middle-aged population. in Atherosclerosis
Elsevier Inc.., 355, E238-E238.
https://doi.org/10.1016/j.atherosclerosis.2022.06.677
Vladimirov S, Gojković T, Zeljković A, Bogavac-Stanojević N, Spasojević-Kalimanovska V. Association between cholesterol synthesis markers and biological sex in the healthy, middle-aged population. in Atherosclerosis. 2022;355:E238-E238.
doi:10.1016/j.atherosclerosis.2022.06.677 .
Vladimirov, Sandra, Gojković, Tamara, Zeljković, Aleksandra, Bogavac-Stanojević, Nataša, Spasojević-Kalimanovska, Vesna, "Association between cholesterol synthesis markers and biological sex in the healthy, middle-aged population" in Atherosclerosis, 355 (2022):E238-E238,
https://doi.org/10.1016/j.atherosclerosis.2022.06.677 . .

Effects of monacolin K, and B1, C and K2 vitamins -Containing nutraceutical on cholesterol homeostasis re-establishment and CVD risk reduction in hypercholesterolemic subjects

Gojković, Tamara; Vladimirov, Sandra; Kotur-Stevuljević, Jelena; Bogavac-Stanojević, Nataša; Zeljković, Aleksandra; Vekić, Jelena; Antonić, Tamara; Spasojević-Kalimanovska, Vesna

(Elsevier B.V., 2022)

TY  - CONF
AU  - Gojković, Tamara
AU  - Vladimirov, Sandra
AU  - Kotur-Stevuljević, Jelena
AU  - Bogavac-Stanojević, Nataša
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Antonić, Tamara
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4358
PB  - Elsevier B.V.
C3  - Clinica Chimica Acta
T1  - Effects of monacolin K, and B1, C and K2 vitamins -Containing nutraceutical on cholesterol homeostasis re-establishment and CVD risk reduction in hypercholesterolemic subjects
VL  - 530
IS  - Supplement 1
SP  - S24
EP  - S24
DO  - 10.1016/j.cca.2022.04.343
ER  - 
@conference{
author = "Gojković, Tamara and Vladimirov, Sandra and Kotur-Stevuljević, Jelena and Bogavac-Stanojević, Nataša and Zeljković, Aleksandra and Vekić, Jelena and Antonić, Tamara and Spasojević-Kalimanovska, Vesna",
year = "2022",
publisher = "Elsevier B.V.",
journal = "Clinica Chimica Acta",
title = "Effects of monacolin K, and B1, C and K2 vitamins -Containing nutraceutical on cholesterol homeostasis re-establishment and CVD risk reduction in hypercholesterolemic subjects",
volume = "530",
number = "Supplement 1",
pages = "S24-S24",
doi = "10.1016/j.cca.2022.04.343"
}
Gojković, T., Vladimirov, S., Kotur-Stevuljević, J., Bogavac-Stanojević, N., Zeljković, A., Vekić, J., Antonić, T.,& Spasojević-Kalimanovska, V.. (2022). Effects of monacolin K, and B1, C and K2 vitamins -Containing nutraceutical on cholesterol homeostasis re-establishment and CVD risk reduction in hypercholesterolemic subjects. in Clinica Chimica Acta
Elsevier B.V.., 530(Supplement 1), S24-S24.
https://doi.org/10.1016/j.cca.2022.04.343
Gojković T, Vladimirov S, Kotur-Stevuljević J, Bogavac-Stanojević N, Zeljković A, Vekić J, Antonić T, Spasojević-Kalimanovska V. Effects of monacolin K, and B1, C and K2 vitamins -Containing nutraceutical on cholesterol homeostasis re-establishment and CVD risk reduction in hypercholesterolemic subjects. in Clinica Chimica Acta. 2022;530(Supplement 1):S24-S24.
doi:10.1016/j.cca.2022.04.343 .
Gojković, Tamara, Vladimirov, Sandra, Kotur-Stevuljević, Jelena, Bogavac-Stanojević, Nataša, Zeljković, Aleksandra, Vekić, Jelena, Antonić, Tamara, Spasojević-Kalimanovska, Vesna, "Effects of monacolin K, and B1, C and K2 vitamins -Containing nutraceutical on cholesterol homeostasis re-establishment and CVD risk reduction in hypercholesterolemic subjects" in Clinica Chimica Acta, 530, no. Supplement 1 (2022):S24-S24,
https://doi.org/10.1016/j.cca.2022.04.343 . .

Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia

Lalosević, Miodrag; Kotur-Stevuljević, Jelena; Vekić, Jelena; Rizzo, Manfredi; Kosanović, Tijana; Blagojević-Perović, Ivana; Zeljković, Aleksandra; Jeremić, Danilo; Mihajlović, Marija; Petković, Aleksa; Hajdarpasić, Lejla; Đorđević, Marjana; Dobrilović, Violeta; Erceg, Sanja; Vujčić, Sanja; Marjanović, Jelena; Jovanović-Milijić, Jovana; Saponjski, Jovica; Bogavac-Stanojević, Nataša

(Hindawi Limited, 2022)

TY  - JOUR
AU  - Lalosević, Miodrag
AU  - Kotur-Stevuljević, Jelena
AU  - Vekić, Jelena
AU  - Rizzo, Manfredi
AU  - Kosanović, Tijana
AU  - Blagojević-Perović, Ivana
AU  - Zeljković, Aleksandra
AU  - Jeremić, Danilo
AU  - Mihajlović, Marija
AU  - Petković, Aleksa
AU  - Hajdarpasić, Lejla
AU  - Đorđević, Marjana
AU  - Dobrilović, Violeta
AU  - Erceg, Sanja
AU  - Vujčić, Sanja
AU  - Marjanović, Jelena
AU  - Jovanović-Milijić, Jovana
AU  - Saponjski, Jovica
AU  - Bogavac-Stanojević, Nataša
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4335
AB  - Background. Metabolic alterations, particularly disorders of lipoprotein metabolism in COVID-19, may affect the course and outcome of the disease. This study aims at evaluating the lipoprotein profile and redox status in SARS-CoV-2 infected patients with different pneumonia severity and their association with lethal outcomes. Methods. The prospective cohort study was performed on 98 COVID-19 patients with mild, moderate, and severe pneumonia. Lipid and inflammatory parameters, lipoprotein subclasses, and redox status biomarkers were determined at the study entry and after one week. Results. Compared to patients with mild and moderate pneumonia, severely ill patients had higher oxidised low-density lipoprotein (oxLDL) and malondialdehyde levels and lower high-density lipoprotein cholesterol (HDL-C) concentrations and paraoxonase 1 activity. Reduction in the proportion of large HDL 2a subclasses with a concomitant increase in the proportion of smallest HDL 3c and small dense LDL (sdLDL) particles was observed in patients with severe disease during the time. However, these changes were reversed in the mild and moderate groups. The results showed a positive association between changes in oxLDL and total antioxidative status. However, prooxidants and antioxidants in plasma were lower in patients with lethal outcomes. Conclusions. Increased levels of oxLDL and sdLDL particles may contribute to the severity of COVID-19. The role of oxidative stress should be clarified in further studies, mainly its association with lethal outcomes.
PB  - Hindawi Limited
T2  - Oxidative Medicine and Cellular Longevity
T1  - Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia
VL  - 2022
DO  - 10.1155/2022/8067857
ER  - 
@article{
author = "Lalosević, Miodrag and Kotur-Stevuljević, Jelena and Vekić, Jelena and Rizzo, Manfredi and Kosanović, Tijana and Blagojević-Perović, Ivana and Zeljković, Aleksandra and Jeremić, Danilo and Mihajlović, Marija and Petković, Aleksa and Hajdarpasić, Lejla and Đorđević, Marjana and Dobrilović, Violeta and Erceg, Sanja and Vujčić, Sanja and Marjanović, Jelena and Jovanović-Milijić, Jovana and Saponjski, Jovica and Bogavac-Stanojević, Nataša",
year = "2022",
abstract = "Background. Metabolic alterations, particularly disorders of lipoprotein metabolism in COVID-19, may affect the course and outcome of the disease. This study aims at evaluating the lipoprotein profile and redox status in SARS-CoV-2 infected patients with different pneumonia severity and their association with lethal outcomes. Methods. The prospective cohort study was performed on 98 COVID-19 patients with mild, moderate, and severe pneumonia. Lipid and inflammatory parameters, lipoprotein subclasses, and redox status biomarkers were determined at the study entry and after one week. Results. Compared to patients with mild and moderate pneumonia, severely ill patients had higher oxidised low-density lipoprotein (oxLDL) and malondialdehyde levels and lower high-density lipoprotein cholesterol (HDL-C) concentrations and paraoxonase 1 activity. Reduction in the proportion of large HDL 2a subclasses with a concomitant increase in the proportion of smallest HDL 3c and small dense LDL (sdLDL) particles was observed in patients with severe disease during the time. However, these changes were reversed in the mild and moderate groups. The results showed a positive association between changes in oxLDL and total antioxidative status. However, prooxidants and antioxidants in plasma were lower in patients with lethal outcomes. Conclusions. Increased levels of oxLDL and sdLDL particles may contribute to the severity of COVID-19. The role of oxidative stress should be clarified in further studies, mainly its association with lethal outcomes.",
publisher = "Hindawi Limited",
journal = "Oxidative Medicine and Cellular Longevity",
title = "Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia",
volume = "2022",
doi = "10.1155/2022/8067857"
}
Lalosević, M., Kotur-Stevuljević, J., Vekić, J., Rizzo, M., Kosanović, T., Blagojević-Perović, I., Zeljković, A., Jeremić, D., Mihajlović, M., Petković, A., Hajdarpasić, L., Đorđević, M., Dobrilović, V., Erceg, S., Vujčić, S., Marjanović, J., Jovanović-Milijić, J., Saponjski, J.,& Bogavac-Stanojević, N.. (2022). Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia. in Oxidative Medicine and Cellular Longevity
Hindawi Limited., 2022.
https://doi.org/10.1155/2022/8067857
Lalosević M, Kotur-Stevuljević J, Vekić J, Rizzo M, Kosanović T, Blagojević-Perović I, Zeljković A, Jeremić D, Mihajlović M, Petković A, Hajdarpasić L, Đorđević M, Dobrilović V, Erceg S, Vujčić S, Marjanović J, Jovanović-Milijić J, Saponjski J, Bogavac-Stanojević N. Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia. in Oxidative Medicine and Cellular Longevity. 2022;2022.
doi:10.1155/2022/8067857 .
Lalosević, Miodrag, Kotur-Stevuljević, Jelena, Vekić, Jelena, Rizzo, Manfredi, Kosanović, Tijana, Blagojević-Perović, Ivana, Zeljković, Aleksandra, Jeremić, Danilo, Mihajlović, Marija, Petković, Aleksa, Hajdarpasić, Lejla, Đorđević, Marjana, Dobrilović, Violeta, Erceg, Sanja, Vujčić, Sanja, Marjanović, Jelena, Jovanović-Milijić, Jovana, Saponjski, Jovica, Bogavac-Stanojević, Nataša, "Alteration in Redox Status and Lipoprotein Profile in COVID-19 Patients with Mild, Moderate, and Severe Pneumonia" in Oxidative Medicine and Cellular Longevity, 2022 (2022),
https://doi.org/10.1155/2022/8067857 . .
5
5

Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings

Mihajlović, Marija; Ninić, Ana; Ostojić, Marija; Sopić, Miron; Stefanović, Aleksandra; Vekić, Jelena; Antonić, Tamara; Zeljković, Dejan; Trifunović, Branislav; Spasojević-Kalimanovska, Vesna; Bogavac-Stanojević, Nataša; Jančić, Ivan; Zeljković, Aleksandra

(MDPI, 2022)

TY  - JOUR
AU  - Mihajlović, Marija
AU  - Ninić, Ana
AU  - Ostojić, Marija
AU  - Sopić, Miron
AU  - Stefanović, Aleksandra
AU  - Vekić, Jelena
AU  - Antonić, Tamara
AU  - Zeljković, Dejan
AU  - Trifunović, Branislav
AU  - Spasojević-Kalimanovska, Vesna
AU  - Bogavac-Stanojević, Nataša
AU  - Jančić, Ivan
AU  - Zeljković, Aleksandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4327
AB  - Adiponectin (ADIPOQ) as both a regulator of metabolic homeostasis and a protein involved in immune response might be of particular interest to contemporary laboratory medicine, especially in terms of minimally invasive diagnostics. The diverse roles of ADIPOQ with regard to the immune and metabolic aspects of colorectal carcinogenesis have been proposed. However, the expression of its receptors ADIPOR1 and ADIPOR2 is scarcely explored in peripheral blood mononuclear cells (PBMCs). Moreover, ADIPORs’ relationships with the immune response mediator TNF-α have not been previously investigated in the PBMCs of CRC patients. This study used both in silico and observational case–control analyses with the aim of exploring the association of ADIPOR gene expression and ADIPOQ single nucleotide polymorphisms (SNPs) with the inflammatory marker TNF-α and lipid status parameters in patients with CRC. Publicly available transcriptomic datasets (GSE47756, GSE44076) obtained from analyses of monocytes and CRC tissue samples were employed for the in silico evaluation of ADIPORs’ specific genetic traits. GSE47756 and GSE44076 datasets were processed with GSEA software to provide a genetic fingertip of different signaling pathways associated with ADIPORs’ mRNA levels. The case–control aspect of the study included the PBMC samples of 73 patients diagnosed with CRC and 80 healthy volunteers. The PCR method was carried out for the PBMC gene expression analysis (ADIPOR1, ADIPOR2, TNF-α mRNA levels) and for the subjects’ genotyping (ADIPOQ rs266729, ADIPOR1 rs7539542). GSEA showed significant associations of ADIPOR mRNA expression with gene sets related to metabolic and immune homeostasis in both datasets. The case–control study revealed the association of ADIPOR1 rs7539542 with reduced lipid status parameters in CRC. In addition, PBMC ADIPOR1 mRNA levels decreased in CRC (p < 0.001), whereas ADIPOR2 mRNA did not differ between the groups (p = 0.442). A reduction in PBMC TNF-α mRNA levels was noted in CRC (p < 0.05). Our results indicate that ADIPOR1 and ADIPOR2 play a significant role in the alteration of both metabolic and immune homeostasis during the progression of CRC. For the first time, ADIPOR1 is shown to be a specific receptor for mediating ADIPOQ’s effects in the PBMCs of CRC patients.
PB  - MDPI
T2  - International Journal of Environmental Research and Public Health
T1  - Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings
VL  - 19
IS  - 22
DO  - 10.3390/ijerph192214995
ER  - 
@article{
author = "Mihajlović, Marija and Ninić, Ana and Ostojić, Marija and Sopić, Miron and Stefanović, Aleksandra and Vekić, Jelena and Antonić, Tamara and Zeljković, Dejan and Trifunović, Branislav and Spasojević-Kalimanovska, Vesna and Bogavac-Stanojević, Nataša and Jančić, Ivan and Zeljković, Aleksandra",
year = "2022",
abstract = "Adiponectin (ADIPOQ) as both a regulator of metabolic homeostasis and a protein involved in immune response might be of particular interest to contemporary laboratory medicine, especially in terms of minimally invasive diagnostics. The diverse roles of ADIPOQ with regard to the immune and metabolic aspects of colorectal carcinogenesis have been proposed. However, the expression of its receptors ADIPOR1 and ADIPOR2 is scarcely explored in peripheral blood mononuclear cells (PBMCs). Moreover, ADIPORs’ relationships with the immune response mediator TNF-α have not been previously investigated in the PBMCs of CRC patients. This study used both in silico and observational case–control analyses with the aim of exploring the association of ADIPOR gene expression and ADIPOQ single nucleotide polymorphisms (SNPs) with the inflammatory marker TNF-α and lipid status parameters in patients with CRC. Publicly available transcriptomic datasets (GSE47756, GSE44076) obtained from analyses of monocytes and CRC tissue samples were employed for the in silico evaluation of ADIPORs’ specific genetic traits. GSE47756 and GSE44076 datasets were processed with GSEA software to provide a genetic fingertip of different signaling pathways associated with ADIPORs’ mRNA levels. The case–control aspect of the study included the PBMC samples of 73 patients diagnosed with CRC and 80 healthy volunteers. The PCR method was carried out for the PBMC gene expression analysis (ADIPOR1, ADIPOR2, TNF-α mRNA levels) and for the subjects’ genotyping (ADIPOQ rs266729, ADIPOR1 rs7539542). GSEA showed significant associations of ADIPOR mRNA expression with gene sets related to metabolic and immune homeostasis in both datasets. The case–control study revealed the association of ADIPOR1 rs7539542 with reduced lipid status parameters in CRC. In addition, PBMC ADIPOR1 mRNA levels decreased in CRC (p < 0.001), whereas ADIPOR2 mRNA did not differ between the groups (p = 0.442). A reduction in PBMC TNF-α mRNA levels was noted in CRC (p < 0.05). Our results indicate that ADIPOR1 and ADIPOR2 play a significant role in the alteration of both metabolic and immune homeostasis during the progression of CRC. For the first time, ADIPOR1 is shown to be a specific receptor for mediating ADIPOQ’s effects in the PBMCs of CRC patients.",
publisher = "MDPI",
journal = "International Journal of Environmental Research and Public Health",
title = "Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings",
volume = "19",
number = "22",
doi = "10.3390/ijerph192214995"
}
Mihajlović, M., Ninić, A., Ostojić, M., Sopić, M., Stefanović, A., Vekić, J., Antonić, T., Zeljković, D., Trifunović, B., Spasojević-Kalimanovska, V., Bogavac-Stanojević, N., Jančić, I.,& Zeljković, A.. (2022). Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings. in International Journal of Environmental Research and Public Health
MDPI., 19(22).
https://doi.org/10.3390/ijerph192214995
Mihajlović M, Ninić A, Ostojić M, Sopić M, Stefanović A, Vekić J, Antonić T, Zeljković D, Trifunović B, Spasojević-Kalimanovska V, Bogavac-Stanojević N, Jančić I, Zeljković A. Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings. in International Journal of Environmental Research and Public Health. 2022;19(22).
doi:10.3390/ijerph192214995 .
Mihajlović, Marija, Ninić, Ana, Ostojić, Marija, Sopić, Miron, Stefanović, Aleksandra, Vekić, Jelena, Antonić, Tamara, Zeljković, Dejan, Trifunović, Branislav, Spasojević-Kalimanovska, Vesna, Bogavac-Stanojević, Nataša, Jančić, Ivan, Zeljković, Aleksandra, "Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings" in International Journal of Environmental Research and Public Health, 19, no. 22 (2022),
https://doi.org/10.3390/ijerph192214995 . .
1
2
2

Effects of Apnea, Obesity, and Statin Therapy on Proprotein Convertase Subtilisin/Kexin 9 Levels in Patients with Obstructive Sleep Apnea

Milojević, Ana; Zdravković, Marija; Brajković, Milica; Memon, Lidija; Gardijan, Vera; Vekić, Jelena; Zeljković, Aleksandra; Stefanović, Aleksandra; Mihajlović, Marija; Ivanišević, Jasmina; Bogavac-Stanojević, Nataša; Radosavljević, Vojislav; Spasojević-Kalimanovska, Vesna; Ninić, Ana

(S. Karger AG Basel, 2022)

TY  - JOUR
AU  - Milojević, Ana
AU  - Zdravković, Marija
AU  - Brajković, Milica
AU  - Memon, Lidija
AU  - Gardijan, Vera
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Stefanović, Aleksandra
AU  - Mihajlović, Marija
AU  - Ivanišević, Jasmina
AU  - Bogavac-Stanojević, Nataša
AU  - Radosavljević, Vojislav
AU  - Spasojević-Kalimanovska, Vesna
AU  - Ninić, Ana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4199
AB  - Objectives: Obstructive sleep apnea (OSA) is a common condition closely related to obesity, insulin resistance, dyslipidemia, and cardiovascular disease. The aim of this study was to explore the possible relationship between OSA and proprotein convertase subtilisin/kexin type 9 (PCSK9). Methods: Full-night polysomnography was performed on 150 participants who were divided into three groups: controls, OSA patients on statin therapy, and OSA patients not on statin therapy. Biochemical markers, plasma low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclasses, and PCSK9 were determined. Results: PCSK9 was highest in OSA patients on statins compared to the control group and to OSA patients not on statins (p = 0.036 and p = 0.039, respectively), after adjustment for body mass index (BMI). LDL diameter was greater in OSA patients not on statins compared to OSA patients on statins (p = 0.032). PCSK9 was highest in the group of patients with all three risk factors (diagnosed OSA, statins, BMI ≥25 kg/m2) compared to groups with no, one, and two risk factors (p = 0.031, p = 0.001, and p = 0.029, respectively). Presence of OSA, statin therapy, and BMI ≥25 kg/m2 when combined were independently associated with higher levels of PCSK9 when adjusted for antihypertensive therapy, small dense LDL, and HDL 3c subclass (odds ratio = 2.849; interquartile range [1.026–7.912], p = 0.044). Conclusion: Statin therapy was closely related to PCSK9. OSA along with obesity and statin use induces elevation of PCSK9.
PB  - S. Karger AG Basel
T2  - Medical Principles and Practice
T1  - Effects of Apnea, Obesity, and Statin Therapy on
Proprotein Convertase Subtilisin/Kexin 9 Levels
in Patients with Obstructive Sleep Apnea
VL  - 31
IS  - 3
SP  - 293
EP  - 300
DO  - 10.1159/000524087
ER  - 
@article{
author = "Milojević, Ana and Zdravković, Marija and Brajković, Milica and Memon, Lidija and Gardijan, Vera and Vekić, Jelena and Zeljković, Aleksandra and Stefanović, Aleksandra and Mihajlović, Marija and Ivanišević, Jasmina and Bogavac-Stanojević, Nataša and Radosavljević, Vojislav and Spasojević-Kalimanovska, Vesna and Ninić, Ana",
year = "2022",
abstract = "Objectives: Obstructive sleep apnea (OSA) is a common condition closely related to obesity, insulin resistance, dyslipidemia, and cardiovascular disease. The aim of this study was to explore the possible relationship between OSA and proprotein convertase subtilisin/kexin type 9 (PCSK9). Methods: Full-night polysomnography was performed on 150 participants who were divided into three groups: controls, OSA patients on statin therapy, and OSA patients not on statin therapy. Biochemical markers, plasma low-density lipoprotein (LDL) and high-density lipoprotein (HDL) subclasses, and PCSK9 were determined. Results: PCSK9 was highest in OSA patients on statins compared to the control group and to OSA patients not on statins (p = 0.036 and p = 0.039, respectively), after adjustment for body mass index (BMI). LDL diameter was greater in OSA patients not on statins compared to OSA patients on statins (p = 0.032). PCSK9 was highest in the group of patients with all three risk factors (diagnosed OSA, statins, BMI ≥25 kg/m2) compared to groups with no, one, and two risk factors (p = 0.031, p = 0.001, and p = 0.029, respectively). Presence of OSA, statin therapy, and BMI ≥25 kg/m2 when combined were independently associated with higher levels of PCSK9 when adjusted for antihypertensive therapy, small dense LDL, and HDL 3c subclass (odds ratio = 2.849; interquartile range [1.026–7.912], p = 0.044). Conclusion: Statin therapy was closely related to PCSK9. OSA along with obesity and statin use induces elevation of PCSK9.",
publisher = "S. Karger AG Basel",
journal = "Medical Principles and Practice",
title = "Effects of Apnea, Obesity, and Statin Therapy on
Proprotein Convertase Subtilisin/Kexin 9 Levels
in Patients with Obstructive Sleep Apnea",
volume = "31",
number = "3",
pages = "293-300",
doi = "10.1159/000524087"
}
Milojević, A., Zdravković, M., Brajković, M., Memon, L., Gardijan, V., Vekić, J., Zeljković, A., Stefanović, A., Mihajlović, M., Ivanišević, J., Bogavac-Stanojević, N., Radosavljević, V., Spasojević-Kalimanovska, V.,& Ninić, A.. (2022). Effects of Apnea, Obesity, and Statin Therapy on
Proprotein Convertase Subtilisin/Kexin 9 Levels
in Patients with Obstructive Sleep Apnea. in Medical Principles and Practice
S. Karger AG Basel., 31(3), 293-300.
https://doi.org/10.1159/000524087
Milojević A, Zdravković M, Brajković M, Memon L, Gardijan V, Vekić J, Zeljković A, Stefanović A, Mihajlović M, Ivanišević J, Bogavac-Stanojević N, Radosavljević V, Spasojević-Kalimanovska V, Ninić A. Effects of Apnea, Obesity, and Statin Therapy on
Proprotein Convertase Subtilisin/Kexin 9 Levels
in Patients with Obstructive Sleep Apnea. in Medical Principles and Practice. 2022;31(3):293-300.
doi:10.1159/000524087 .
Milojević, Ana, Zdravković, Marija, Brajković, Milica, Memon, Lidija, Gardijan, Vera, Vekić, Jelena, Zeljković, Aleksandra, Stefanović, Aleksandra, Mihajlović, Marija, Ivanišević, Jasmina, Bogavac-Stanojević, Nataša, Radosavljević, Vojislav, Spasojević-Kalimanovska, Vesna, Ninić, Ana, "Effects of Apnea, Obesity, and Statin Therapy on
Proprotein Convertase Subtilisin/Kexin 9 Levels
in Patients with Obstructive Sleep Apnea" in Medical Principles and Practice, 31, no. 3 (2022):293-300,
https://doi.org/10.1159/000524087 . .

Alterations of cholesterol synthesis and absorption in obstructive sleep apnea: Influence of obesity and disease severity

Zeljković, Aleksandra; Milojević, Ana; Vladimirov, Sandra; Zdravković, Marija; Memon, Lidija; Brajković, Milica; Gardijan, Vera; Gojković, Tamara; Stefanović, Aleksandra; Miljković-Trailović, Milica; Spasojević-Kalimanovska, Vesna; Ninić, Ana

(Elsevier B.V., 2022)

TY  - JOUR
AU  - Zeljković, Aleksandra
AU  - Milojević, Ana
AU  - Vladimirov, Sandra
AU  - Zdravković, Marija
AU  - Memon, Lidija
AU  - Brajković, Milica
AU  - Gardijan, Vera
AU  - Gojković, Tamara
AU  - Stefanović, Aleksandra
AU  - Miljković-Trailović, Milica
AU  - Spasojević-Kalimanovska, Vesna
AU  - Ninić, Ana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4322
AB  - Background and aims: Obstructive sleep apnea (OSA) is closely linked to obesity and related adverse metabolic changes, including dyslipidemia. However, it is not clear whether OSA is an independent contributing factor to dyslipidemia, or the observed association is a reflection of a concomitant presence of obesity. Additionally, dyslipidemia is usually evaluated through measurement of parameters of routine lipid status, while more precise evaluation of lipid homeostasis is rarely performed in OSA. In this study, we analyzed markers of cholesterol synthesis and absorption in patients with OSA with respect to the presence of obesity and the disease severity. Methods and results: This study enrolled 116 OSA patients. Concentrations of non-cholesterol sterols (NCS), measured by LC-MS/MS, were used as markers of cholesterol synthesis and absorption. Apnea-hypopnea index (AHI) and oxygen saturation (SaO2) were utilized as markers of OSA severity. Serum lipid status parameters were determined by routine enzymatic methods. Markers of cholesterol synthesis were increased (P = 0.005), whilst markers of cholesterol absorption decreased (P = 0.001) in obese OSA patients. Cholesterol synthesis/absorption ratio was elevated in obese subjects (P < 0.001). Concentration of cholesterol synthesis marker lathosterol was significantly higher in subjects with severe OSA (P = 0.014) and we observed a trend of decreased cholesterol absorption in these patients. AHI was revealed as an independent determinant of lathosterol concentration (P = 0.022). Conclusions: Our results suggest that the presence of obesity and severe forms of OSA is characterized by elevated endogenous cholesterol synthesis. AHI was singled out as an independent determinant of the serum level of cholesterol synthesis marker lathosterol.
PB  - Elsevier B.V.
T2  - Nutrition, Metabolism and Cardiovascular Diseases
T1  - Alterations of cholesterol synthesis and absorption in obstructive sleep apnea: Influence of obesity and disease severity
VL  - 32
IS  - 12
SP  - 2848
EP  - 2857
DO  - 10.1016/j.numecd.2022.09.006
ER  - 
@article{
author = "Zeljković, Aleksandra and Milojević, Ana and Vladimirov, Sandra and Zdravković, Marija and Memon, Lidija and Brajković, Milica and Gardijan, Vera and Gojković, Tamara and Stefanović, Aleksandra and Miljković-Trailović, Milica and Spasojević-Kalimanovska, Vesna and Ninić, Ana",
year = "2022",
abstract = "Background and aims: Obstructive sleep apnea (OSA) is closely linked to obesity and related adverse metabolic changes, including dyslipidemia. However, it is not clear whether OSA is an independent contributing factor to dyslipidemia, or the observed association is a reflection of a concomitant presence of obesity. Additionally, dyslipidemia is usually evaluated through measurement of parameters of routine lipid status, while more precise evaluation of lipid homeostasis is rarely performed in OSA. In this study, we analyzed markers of cholesterol synthesis and absorption in patients with OSA with respect to the presence of obesity and the disease severity. Methods and results: This study enrolled 116 OSA patients. Concentrations of non-cholesterol sterols (NCS), measured by LC-MS/MS, were used as markers of cholesterol synthesis and absorption. Apnea-hypopnea index (AHI) and oxygen saturation (SaO2) were utilized as markers of OSA severity. Serum lipid status parameters were determined by routine enzymatic methods. Markers of cholesterol synthesis were increased (P = 0.005), whilst markers of cholesterol absorption decreased (P = 0.001) in obese OSA patients. Cholesterol synthesis/absorption ratio was elevated in obese subjects (P < 0.001). Concentration of cholesterol synthesis marker lathosterol was significantly higher in subjects with severe OSA (P = 0.014) and we observed a trend of decreased cholesterol absorption in these patients. AHI was revealed as an independent determinant of lathosterol concentration (P = 0.022). Conclusions: Our results suggest that the presence of obesity and severe forms of OSA is characterized by elevated endogenous cholesterol synthesis. AHI was singled out as an independent determinant of the serum level of cholesterol synthesis marker lathosterol.",
publisher = "Elsevier B.V.",
journal = "Nutrition, Metabolism and Cardiovascular Diseases",
title = "Alterations of cholesterol synthesis and absorption in obstructive sleep apnea: Influence of obesity and disease severity",
volume = "32",
number = "12",
pages = "2848-2857",
doi = "10.1016/j.numecd.2022.09.006"
}
Zeljković, A., Milojević, A., Vladimirov, S., Zdravković, M., Memon, L., Brajković, M., Gardijan, V., Gojković, T., Stefanović, A., Miljković-Trailović, M., Spasojević-Kalimanovska, V.,& Ninić, A.. (2022). Alterations of cholesterol synthesis and absorption in obstructive sleep apnea: Influence of obesity and disease severity. in Nutrition, Metabolism and Cardiovascular Diseases
Elsevier B.V.., 32(12), 2848-2857.
https://doi.org/10.1016/j.numecd.2022.09.006
Zeljković A, Milojević A, Vladimirov S, Zdravković M, Memon L, Brajković M, Gardijan V, Gojković T, Stefanović A, Miljković-Trailović M, Spasojević-Kalimanovska V, Ninić A. Alterations of cholesterol synthesis and absorption in obstructive sleep apnea: Influence of obesity and disease severity. in Nutrition, Metabolism and Cardiovascular Diseases. 2022;32(12):2848-2857.
doi:10.1016/j.numecd.2022.09.006 .
Zeljković, Aleksandra, Milojević, Ana, Vladimirov, Sandra, Zdravković, Marija, Memon, Lidija, Brajković, Milica, Gardijan, Vera, Gojković, Tamara, Stefanović, Aleksandra, Miljković-Trailović, Milica, Spasojević-Kalimanovska, Vesna, Ninić, Ana, "Alterations of cholesterol synthesis and absorption in obstructive sleep apnea: Influence of obesity and disease severity" in Nutrition, Metabolism and Cardiovascular Diseases, 32, no. 12 (2022):2848-2857,
https://doi.org/10.1016/j.numecd.2022.09.006 . .
1
3
3

Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome

Zeljković, Aleksandra; Ardalić, Daniela; Vekić, Jelena; Antonić, Tamara; Vladimirov, Sandra; Rizzo, Manfredi; Gojković, Tamara; Ivanišević, Jasmina; Mihajlović, Marija; Vujčić, Sanja; Cabunac, Petar; Spasojević-Kalimanovska, Vesna; Miković, Željko; Stefanović, Aleksandra

(MDPI, 2022)

TY  - JOUR
AU  - Zeljković, Aleksandra
AU  - Ardalić, Daniela
AU  - Vekić, Jelena
AU  - Antonić, Tamara
AU  - Vladimirov, Sandra
AU  - Rizzo, Manfredi
AU  - Gojković, Tamara
AU  - Ivanišević, Jasmina
AU  - Mihajlović, Marija
AU  - Vujčić, Sanja
AU  - Cabunac, Petar
AU  - Spasojević-Kalimanovska, Vesna
AU  - Miković, Željko
AU  - Stefanović, Aleksandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4314
AB  - Metabolic disorders in pregnancy, particularly gestational diabetes mellitus (GDM), are associated with an increased risk for adverse pregnancy outcome and long-term cardiometabolic health of mother and child. This study analyzed changes of serum cholesterol synthesis and absorption markers during the course of high-risk pregnancies, with respect to the development of GDM. Possible associations of maternal lipid biomarkers with neonatal characteristics were also investigated. The study included 63 women with high risk for development of pregnancy complications. Size and proportions of small low-density (LDL) and high-density lipoprotein (HDL) particles were assessed across trimesters (T1–T3), as well as concentrations of cholesterol synthesis (lathosterol, desmosterol) and absorption markers (campesterol, β-sitosterol). During the study, 15 women developed GDM, while 48 had no complications (non-GDM). As compared to the non-GDM group, women with GDM had significantly higher triglycerides in each trimester, while having a lower HDL-C level in T3. In addition, they had significantly lower levels of β-sitosterol in T3 (p < 0.05). Cholesterol synthesis markers increased across trimesters in both groups. A decrease in serum β-sitosterol levels during the course of pregnancies affected by GDM was observed. The prevalence of small-sized HDL decreased in non-GDM, while in the GDM group remained unchanged across trimesters. Newborn’s size in the non-GDM group was significantly higher (p < 0.01) and inversely associated with proportions of both small, dense LDL and HDL particles (p < 0.05) in maternal plasma in T1. In conclusion, high-risk pregnancies affected by GDM are characterized by altered cholesterol absorption and HDL maturation. Advanced lipid testing may indicate disturbed lipid homeostasis in GDM.
PB  - MDPI
T2  - Metabolites
T1  - Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome
VL  - 12
IS  - 10
DO  - 10.3390/metabo12100959
ER  - 
@article{
author = "Zeljković, Aleksandra and Ardalić, Daniela and Vekić, Jelena and Antonić, Tamara and Vladimirov, Sandra and Rizzo, Manfredi and Gojković, Tamara and Ivanišević, Jasmina and Mihajlović, Marija and Vujčić, Sanja and Cabunac, Petar and Spasojević-Kalimanovska, Vesna and Miković, Željko and Stefanović, Aleksandra",
year = "2022",
abstract = "Metabolic disorders in pregnancy, particularly gestational diabetes mellitus (GDM), are associated with an increased risk for adverse pregnancy outcome and long-term cardiometabolic health of mother and child. This study analyzed changes of serum cholesterol synthesis and absorption markers during the course of high-risk pregnancies, with respect to the development of GDM. Possible associations of maternal lipid biomarkers with neonatal characteristics were also investigated. The study included 63 women with high risk for development of pregnancy complications. Size and proportions of small low-density (LDL) and high-density lipoprotein (HDL) particles were assessed across trimesters (T1–T3), as well as concentrations of cholesterol synthesis (lathosterol, desmosterol) and absorption markers (campesterol, β-sitosterol). During the study, 15 women developed GDM, while 48 had no complications (non-GDM). As compared to the non-GDM group, women with GDM had significantly higher triglycerides in each trimester, while having a lower HDL-C level in T3. In addition, they had significantly lower levels of β-sitosterol in T3 (p < 0.05). Cholesterol synthesis markers increased across trimesters in both groups. A decrease in serum β-sitosterol levels during the course of pregnancies affected by GDM was observed. The prevalence of small-sized HDL decreased in non-GDM, while in the GDM group remained unchanged across trimesters. Newborn’s size in the non-GDM group was significantly higher (p < 0.01) and inversely associated with proportions of both small, dense LDL and HDL particles (p < 0.05) in maternal plasma in T1. In conclusion, high-risk pregnancies affected by GDM are characterized by altered cholesterol absorption and HDL maturation. Advanced lipid testing may indicate disturbed lipid homeostasis in GDM.",
publisher = "MDPI",
journal = "Metabolites",
title = "Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome",
volume = "12",
number = "10",
doi = "10.3390/metabo12100959"
}
Zeljković, A., Ardalić, D., Vekić, J., Antonić, T., Vladimirov, S., Rizzo, M., Gojković, T., Ivanišević, J., Mihajlović, M., Vujčić, S., Cabunac, P., Spasojević-Kalimanovska, V., Miković, Ž.,& Stefanović, A.. (2022). Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome. in Metabolites
MDPI., 12(10).
https://doi.org/10.3390/metabo12100959
Zeljković A, Ardalić D, Vekić J, Antonić T, Vladimirov S, Rizzo M, Gojković T, Ivanišević J, Mihajlović M, Vujčić S, Cabunac P, Spasojević-Kalimanovska V, Miković Ž, Stefanović A. Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome. in Metabolites. 2022;12(10).
doi:10.3390/metabo12100959 .
Zeljković, Aleksandra, Ardalić, Daniela, Vekić, Jelena, Antonić, Tamara, Vladimirov, Sandra, Rizzo, Manfredi, Gojković, Tamara, Ivanišević, Jasmina, Mihajlović, Marija, Vujčić, Sanja, Cabunac, Petar, Spasojević-Kalimanovska, Vesna, Miković, Željko, Stefanović, Aleksandra, "Effects of Gestational Diabetes Mellitus on Cholesterol Metabolism in Women with High-Risk Pregnancies: Possible Implications for Neonatal Outcome" in Metabolites, 12, no. 10 (2022),
https://doi.org/10.3390/metabo12100959 . .
1
5
3

Lipoproteins and cholesterol homeostasis in paediatric nephrotic syndrome patients

Simachew, Yonas Mulat; Antonić, Tamara; Gojković, Tamara; Vladimirov, Sandra; Mihajlović, Marija; Vujčić, Sanja; Miloševski-Lomić, Gordana; Vekić, Jelena; Zeljković, Aleksandra; Spasojević-Kalimanovska, Vesna; Peco-Antić, Amira; Paripović, Dušan; Stefanović, Aleksandra

(Croatian Society of Medical Biochemistry and Laboratory Medicine, 2022)

TY  - JOUR
AU  - Simachew, Yonas Mulat
AU  - Antonić, Tamara
AU  - Gojković, Tamara
AU  - Vladimirov, Sandra
AU  - Mihajlović, Marija
AU  - Vujčić, Sanja
AU  - Miloševski-Lomić, Gordana
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Spasojević-Kalimanovska, Vesna
AU  - Peco-Antić, Amira
AU  - Paripović, Dušan
AU  - Stefanović, Aleksandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4195
AB  - Introduction  The aim of this study was to investigate lipoprotein particle distributions and the likelihood of achieving cholesterol homeostasis in the remission phase of nephrotic syndrome (NS) in paediatric patients. We hypothesized that lipoprotein particle distributions moved toward less atherogenic profile and that cholesterol homeostasis was achieved. Materials and methods  Thirty-three children, 2 to 9 years old with NS were recruited. Blood sampling took place both in the acute phase and during remission. Serum low-density lipoprotein particles (LDL) and high-density lipoprotein particles (HDL) were separated using non-denaturing polyacrylamide gradient gel (3-31%) electrophoresis. Serum non-cholesterols sterols (NCSs), desmosterol, lathosterol, 7-dehydrocholesterol (7-DHC), campesterol and β-sitosterol were measured by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Results  All patients had desirable serum HDL cholesterol concentrations during remission. The dominant lipoprotein diameters and LDL subclass distribution did not change significantly during follow-up. In contrast, HDL lipoprotein particle distribution shifted towards larger particles. The absolute concentration of desmosterol was significantly lower during remission (P = 0.023). β-sitosterol concentration markedly increased during remission (P = 0.005). Desmosterol/β-sitosterol (P < 0.001) and 7-DHC/β-sitosterol (P = 0.005) ratios significantly declined during disease remission. Conclusions  Favourable changes in the serum lipid profiles, HDL particle subclass distribution and cholesterol metabolism in paediatric patients with NS during remission took place. For the first time, we found that cholesterol homeostasis changed in favour of increased cholesterol absorption during disease remission. Nevertheless, complete cholesterol homeostasis was not achieved during disease remission.
PB  - Croatian Society of Medical Biochemistry and Laboratory Medicine
T2  - Biochemia Medica
T1  - Lipoproteins and cholesterol homeostasis in paediatric nephrotic syndrome patients
VL  - 32
IS  - 2
DO  - 10.11613/BM.2022.020706
ER  - 
@article{
author = "Simachew, Yonas Mulat and Antonić, Tamara and Gojković, Tamara and Vladimirov, Sandra and Mihajlović, Marija and Vujčić, Sanja and Miloševski-Lomić, Gordana and Vekić, Jelena and Zeljković, Aleksandra and Spasojević-Kalimanovska, Vesna and Peco-Antić, Amira and Paripović, Dušan and Stefanović, Aleksandra",
year = "2022",
abstract = "Introduction  The aim of this study was to investigate lipoprotein particle distributions and the likelihood of achieving cholesterol homeostasis in the remission phase of nephrotic syndrome (NS) in paediatric patients. We hypothesized that lipoprotein particle distributions moved toward less atherogenic profile and that cholesterol homeostasis was achieved. Materials and methods  Thirty-three children, 2 to 9 years old with NS were recruited. Blood sampling took place both in the acute phase and during remission. Serum low-density lipoprotein particles (LDL) and high-density lipoprotein particles (HDL) were separated using non-denaturing polyacrylamide gradient gel (3-31%) electrophoresis. Serum non-cholesterols sterols (NCSs), desmosterol, lathosterol, 7-dehydrocholesterol (7-DHC), campesterol and β-sitosterol were measured by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Results  All patients had desirable serum HDL cholesterol concentrations during remission. The dominant lipoprotein diameters and LDL subclass distribution did not change significantly during follow-up. In contrast, HDL lipoprotein particle distribution shifted towards larger particles. The absolute concentration of desmosterol was significantly lower during remission (P = 0.023). β-sitosterol concentration markedly increased during remission (P = 0.005). Desmosterol/β-sitosterol (P < 0.001) and 7-DHC/β-sitosterol (P = 0.005) ratios significantly declined during disease remission. Conclusions  Favourable changes in the serum lipid profiles, HDL particle subclass distribution and cholesterol metabolism in paediatric patients with NS during remission took place. For the first time, we found that cholesterol homeostasis changed in favour of increased cholesterol absorption during disease remission. Nevertheless, complete cholesterol homeostasis was not achieved during disease remission.",
publisher = "Croatian Society of Medical Biochemistry and Laboratory Medicine",
journal = "Biochemia Medica",
title = "Lipoproteins and cholesterol homeostasis in paediatric nephrotic syndrome patients",
volume = "32",
number = "2",
doi = "10.11613/BM.2022.020706"
}
Simachew, Y. M., Antonić, T., Gojković, T., Vladimirov, S., Mihajlović, M., Vujčić, S., Miloševski-Lomić, G., Vekić, J., Zeljković, A., Spasojević-Kalimanovska, V., Peco-Antić, A., Paripović, D.,& Stefanović, A.. (2022). Lipoproteins and cholesterol homeostasis in paediatric nephrotic syndrome patients. in Biochemia Medica
Croatian Society of Medical Biochemistry and Laboratory Medicine., 32(2).
https://doi.org/10.11613/BM.2022.020706
Simachew YM, Antonić T, Gojković T, Vladimirov S, Mihajlović M, Vujčić S, Miloševski-Lomić G, Vekić J, Zeljković A, Spasojević-Kalimanovska V, Peco-Antić A, Paripović D, Stefanović A. Lipoproteins and cholesterol homeostasis in paediatric nephrotic syndrome patients. in Biochemia Medica. 2022;32(2).
doi:10.11613/BM.2022.020706 .
Simachew, Yonas Mulat, Antonić, Tamara, Gojković, Tamara, Vladimirov, Sandra, Mihajlović, Marija, Vujčić, Sanja, Miloševski-Lomić, Gordana, Vekić, Jelena, Zeljković, Aleksandra, Spasojević-Kalimanovska, Vesna, Peco-Antić, Amira, Paripović, Dušan, Stefanović, Aleksandra, "Lipoproteins and cholesterol homeostasis in paediatric nephrotic syndrome patients" in Biochemia Medica, 32, no. 2 (2022),
https://doi.org/10.11613/BM.2022.020706 . .
2
2

Can non-cholesterol sterols indicate the presence of specific dysregulation of cholesterol metabolism in patients with colorectal cancer?

Vladimirov, Sandra; Gojković, Tamara; Zeljković, Aleksandra; Jelić-Ivanović, Zorana; Zeljković, Dejan; Antonić, Tamara; Trifunović, Bratislav; Spasojević-Kalimanovska, Vesna

(Elsevier Inc., 2022)

TY  - JOUR
AU  - Vladimirov, Sandra
AU  - Gojković, Tamara
AU  - Zeljković, Aleksandra
AU  - Jelić-Ivanović, Zorana
AU  - Zeljković, Dejan
AU  - Antonić, Tamara
AU  - Trifunović, Bratislav
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4178
AB  - Colorectal cancer (CRC) is a highly prevalent malignancy. Previous studies suggested that cholesterol might play a signficant role in malignant transformation and proliferation. Non-cholesterol sterols (NCS), which are transported by serum lipoproteins alongside cholesterol, are regarded as cholesterol synthesis and absorption markers. Quantification of NCS in serum and HDL fraction (NCSHDL), could provide a better insight into the cholesterol metabolism. The aim of this study was to examine the status of cholesterol synthesis and cholesterol absorption markers in serum and HDL fraction and explore their interrelation in CRC patients. Current study was designed as observational, case-control study. The study included 73 CRC patients and 95 healthy subjects. NCS and NCSHDL concentrations were determined by HPLC-MS/MS. Based on NCS and NCSHDL concentrations, different cholesterol homeostasis indices were calculated. Patients had significantly lower NCS (P<0.001) and NCSHDL concentrations (P<0.001 for desmosterolHDL; P<0.05 for lathosterolHDL, P=0.001 for campesterolHDL, P<0.001 for β-sitosterolHDL). NCSHDL/NCS (P<0.005 for desmosterolHDL/desmosterol; P<0.05 for lathosterolHDL/lathosterol; P<0.001 for both β-sitosterolHDL/β-sitosterol and campesterolHDL/campesterol) and synthesis to absorption ratio (CSI/CAI) (P<0.005) were increased in CRC patients. Additionally, low serum concentrations of desmosterol (P<0.001; OR=0.329; 95%CI (0.199–0.542)) and campesterol (P<0.001; OR=0.540; 95%CI (0.424–0.687)) were independent predictors of CRC presence. Our data suggest that cholesterol homeostasis in CRC is shifted towards increased synthesis. Relative abundance of NCS in HDL particles is increased, suggesting the possible overproduction of cholesterol precursors in peripheral tissues.
PB  - Elsevier Inc.
T2  - Biochemical Pharmacology
T1  - Can non-cholesterol sterols indicate the presence of specific dysregulation of cholesterol metabolism in patients with colorectal cancer?
VL  - 196
DO  - 10.1016/j.bcp.2021.114595
ER  - 
@article{
author = "Vladimirov, Sandra and Gojković, Tamara and Zeljković, Aleksandra and Jelić-Ivanović, Zorana and Zeljković, Dejan and Antonić, Tamara and Trifunović, Bratislav and Spasojević-Kalimanovska, Vesna",
year = "2022",
abstract = "Colorectal cancer (CRC) is a highly prevalent malignancy. Previous studies suggested that cholesterol might play a signficant role in malignant transformation and proliferation. Non-cholesterol sterols (NCS), which are transported by serum lipoproteins alongside cholesterol, are regarded as cholesterol synthesis and absorption markers. Quantification of NCS in serum and HDL fraction (NCSHDL), could provide a better insight into the cholesterol metabolism. The aim of this study was to examine the status of cholesterol synthesis and cholesterol absorption markers in serum and HDL fraction and explore their interrelation in CRC patients. Current study was designed as observational, case-control study. The study included 73 CRC patients and 95 healthy subjects. NCS and NCSHDL concentrations were determined by HPLC-MS/MS. Based on NCS and NCSHDL concentrations, different cholesterol homeostasis indices were calculated. Patients had significantly lower NCS (P<0.001) and NCSHDL concentrations (P<0.001 for desmosterolHDL; P<0.05 for lathosterolHDL, P=0.001 for campesterolHDL, P<0.001 for β-sitosterolHDL). NCSHDL/NCS (P<0.005 for desmosterolHDL/desmosterol; P<0.05 for lathosterolHDL/lathosterol; P<0.001 for both β-sitosterolHDL/β-sitosterol and campesterolHDL/campesterol) and synthesis to absorption ratio (CSI/CAI) (P<0.005) were increased in CRC patients. Additionally, low serum concentrations of desmosterol (P<0.001; OR=0.329; 95%CI (0.199–0.542)) and campesterol (P<0.001; OR=0.540; 95%CI (0.424–0.687)) were independent predictors of CRC presence. Our data suggest that cholesterol homeostasis in CRC is shifted towards increased synthesis. Relative abundance of NCS in HDL particles is increased, suggesting the possible overproduction of cholesterol precursors in peripheral tissues.",
publisher = "Elsevier Inc.",
journal = "Biochemical Pharmacology",
title = "Can non-cholesterol sterols indicate the presence of specific dysregulation of cholesterol metabolism in patients with colorectal cancer?",
volume = "196",
doi = "10.1016/j.bcp.2021.114595"
}
Vladimirov, S., Gojković, T., Zeljković, A., Jelić-Ivanović, Z., Zeljković, D., Antonić, T., Trifunović, B.,& Spasojević-Kalimanovska, V.. (2022). Can non-cholesterol sterols indicate the presence of specific dysregulation of cholesterol metabolism in patients with colorectal cancer?. in Biochemical Pharmacology
Elsevier Inc.., 196.
https://doi.org/10.1016/j.bcp.2021.114595
Vladimirov S, Gojković T, Zeljković A, Jelić-Ivanović Z, Zeljković D, Antonić T, Trifunović B, Spasojević-Kalimanovska V. Can non-cholesterol sterols indicate the presence of specific dysregulation of cholesterol metabolism in patients with colorectal cancer?. in Biochemical Pharmacology. 2022;196.
doi:10.1016/j.bcp.2021.114595 .
Vladimirov, Sandra, Gojković, Tamara, Zeljković, Aleksandra, Jelić-Ivanović, Zorana, Zeljković, Dejan, Antonić, Tamara, Trifunović, Bratislav, Spasojević-Kalimanovska, Vesna, "Can non-cholesterol sterols indicate the presence of specific dysregulation of cholesterol metabolism in patients with colorectal cancer?" in Biochemical Pharmacology, 196 (2022),
https://doi.org/10.1016/j.bcp.2021.114595 . .
1
11
3
10

Possible role of lead in breast cancer — a case-control study

Anđelković, Milena; Buha-Đorđević, Aleksandra; Javorac, Dragana; Baralić, Katarina; Đukić-Ćosić, Danijela; Repić, Aleksandra; Zeljković, Aleksandra; Vekić, Jelena; Čolaković, Nataša; Bulat, Zorica

(Springer Nature, 2022)

TY  - JOUR
AU  - Anđelković, Milena
AU  - Buha-Đorđević, Aleksandra
AU  - Javorac, Dragana
AU  - Baralić, Katarina
AU  - Đukić-Ćosić, Danijela
AU  - Repić, Aleksandra
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Čolaković, Nataša
AU  - Bulat, Zorica
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4103
AB  - Numerous risk factors have been associated with breast cancer (BC), exposure to metalloestrogen, like lead, being such. Since lead involvement in BC is still equivocal, we focused on lead levels in three compartments of BC patients, blood, healthy, and malignant tissues. Also, as the cholesterol role in cancer development was recognized at the beginning of the twentieth century and led to involvement in lipid profile impairment, we further extend our research on lipid profile and enzymes responsible for maintaining lipid balance in BC patients. Fifty-five women diagnosed with BC were enrolled in the study. Forty-one healthy women represented the control group. Lead levels in blood, healthy surrounding and malignant tissue, and lipid profile parameters in serum, were determined. Higher lead levels were obtained in surrounding healthy tissue samples compared to cancerous tissue samples, while blood lead levels of BC women did not differ significantly from the control group. The altered lipid profile scheme in women diagnosed with breast cancer contained significantly higher triglycerides levels (P < 0.001). Moreover, logistic regression analysis revealed triglycerides as a significant predictor of BC (OR = 2.6; P < 0.01). Although statistical significance was missing for lower paraoxonase-1 (PON-1) activities observed in BC women, multivariate logistic regression singled out PON-1 activities as significant BC predictors. The result of the present study further indicated oxidative status imbalance and tissue levels bioelements perturbation. Obtained results in the present study propose possible lead involvement in BC onset accompanied with bioelements redistribution and oxidative stress occurrence.
PB  - Springer Nature
T2  - Environmental Science and Pollution Research
T1  - Possible role of lead in breast cancer — a case-control study
VL  - 29
SP  - 65211
EP  - 65221
DO  - 10.1007/s11356-022-20439-z
ER  - 
@article{
author = "Anđelković, Milena and Buha-Đorđević, Aleksandra and Javorac, Dragana and Baralić, Katarina and Đukić-Ćosić, Danijela and Repić, Aleksandra and Zeljković, Aleksandra and Vekić, Jelena and Čolaković, Nataša and Bulat, Zorica",
year = "2022",
abstract = "Numerous risk factors have been associated with breast cancer (BC), exposure to metalloestrogen, like lead, being such. Since lead involvement in BC is still equivocal, we focused on lead levels in three compartments of BC patients, blood, healthy, and malignant tissues. Also, as the cholesterol role in cancer development was recognized at the beginning of the twentieth century and led to involvement in lipid profile impairment, we further extend our research on lipid profile and enzymes responsible for maintaining lipid balance in BC patients. Fifty-five women diagnosed with BC were enrolled in the study. Forty-one healthy women represented the control group. Lead levels in blood, healthy surrounding and malignant tissue, and lipid profile parameters in serum, were determined. Higher lead levels were obtained in surrounding healthy tissue samples compared to cancerous tissue samples, while blood lead levels of BC women did not differ significantly from the control group. The altered lipid profile scheme in women diagnosed with breast cancer contained significantly higher triglycerides levels (P < 0.001). Moreover, logistic regression analysis revealed triglycerides as a significant predictor of BC (OR = 2.6; P < 0.01). Although statistical significance was missing for lower paraoxonase-1 (PON-1) activities observed in BC women, multivariate logistic regression singled out PON-1 activities as significant BC predictors. The result of the present study further indicated oxidative status imbalance and tissue levels bioelements perturbation. Obtained results in the present study propose possible lead involvement in BC onset accompanied with bioelements redistribution and oxidative stress occurrence.",
publisher = "Springer Nature",
journal = "Environmental Science and Pollution Research",
title = "Possible role of lead in breast cancer — a case-control study",
volume = "29",
pages = "65211-65221",
doi = "10.1007/s11356-022-20439-z"
}
Anđelković, M., Buha-Đorđević, A., Javorac, D., Baralić, K., Đukić-Ćosić, D., Repić, A., Zeljković, A., Vekić, J., Čolaković, N.,& Bulat, Z.. (2022). Possible role of lead in breast cancer — a case-control study. in Environmental Science and Pollution Research
Springer Nature., 29, 65211-65221.
https://doi.org/10.1007/s11356-022-20439-z
Anđelković M, Buha-Đorđević A, Javorac D, Baralić K, Đukić-Ćosić D, Repić A, Zeljković A, Vekić J, Čolaković N, Bulat Z. Possible role of lead in breast cancer — a case-control study. in Environmental Science and Pollution Research. 2022;29:65211-65221.
doi:10.1007/s11356-022-20439-z .
Anđelković, Milena, Buha-Đorđević, Aleksandra, Javorac, Dragana, Baralić, Katarina, Đukić-Ćosić, Danijela, Repić, Aleksandra, Zeljković, Aleksandra, Vekić, Jelena, Čolaković, Nataša, Bulat, Zorica, "Possible role of lead in breast cancer — a case-control study" in Environmental Science and Pollution Research, 29 (2022):65211-65221,
https://doi.org/10.1007/s11356-022-20439-z . .
1
3
3

Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL

Vekić, Jelena; Zeljković, Aleksandra; Stefanović, Aleksandra; Bogavac-Stanojević, Nataša; Ilias, Ioannis; Silva-Nunes, José; Pantea Stoian, Anca; Janez, Andrej; Rizzo, Manfredi

(MDPI, 2022)

TY  - JOUR
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Stefanović, Aleksandra
AU  - Bogavac-Stanojević, Nataša
AU  - Ilias, Ioannis
AU  - Silva-Nunes, José
AU  - Pantea Stoian, Anca
AU  - Janez, Andrej
AU  - Rizzo, Manfredi
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4100
AB  - Compelling evidence supports the causative link between increased levels of low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) development. For that reason, the principal aim of primary and secondary cardiovascular prevention is to reach and sustain recommended LDL-C goals. Although there is a considerable body of evidence that shows that lowering LDL-C levels is directly associated with CVD risk reduction, recent data shows that the majority of patients across Europe cannot achieve their LDL-C targets. In attempting to address this matter, a new overarching concept of a lipid-lowering approach, comprising of even more intensive, much earlier and longer intervention to reduce LDL-C level, was recently proposed for high-risk patients. Another important concern is the residual risk for recurrent cardiovascular events despite optimal LDL-C reduction, suggesting that novel lipid biomarkers should also be considered as potential therapeutic targets. Among them, small dense LDL particles (sdLDL) seem to have the most significant potential for therapeutic modulation. This paper discusses the potential of traditional and emerging lipid-lowering approaches for cardiovascular prevention by targeting sdLDL particles.
PB  - MDPI
T2  - Pharmaceutics
T1  - Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL
VL  - 14
IS  - 4
DO  - 10.3390/pharmaceutics14040825
ER  - 
@article{
author = "Vekić, Jelena and Zeljković, Aleksandra and Stefanović, Aleksandra and Bogavac-Stanojević, Nataša and Ilias, Ioannis and Silva-Nunes, José and Pantea Stoian, Anca and Janez, Andrej and Rizzo, Manfredi",
year = "2022",
abstract = "Compelling evidence supports the causative link between increased levels of low-density lipoprotein cholesterol (LDL-C) and atherosclerotic cardiovascular disease (CVD) development. For that reason, the principal aim of primary and secondary cardiovascular prevention is to reach and sustain recommended LDL-C goals. Although there is a considerable body of evidence that shows that lowering LDL-C levels is directly associated with CVD risk reduction, recent data shows that the majority of patients across Europe cannot achieve their LDL-C targets. In attempting to address this matter, a new overarching concept of a lipid-lowering approach, comprising of even more intensive, much earlier and longer intervention to reduce LDL-C level, was recently proposed for high-risk patients. Another important concern is the residual risk for recurrent cardiovascular events despite optimal LDL-C reduction, suggesting that novel lipid biomarkers should also be considered as potential therapeutic targets. Among them, small dense LDL particles (sdLDL) seem to have the most significant potential for therapeutic modulation. This paper discusses the potential of traditional and emerging lipid-lowering approaches for cardiovascular prevention by targeting sdLDL particles.",
publisher = "MDPI",
journal = "Pharmaceutics",
title = "Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL",
volume = "14",
number = "4",
doi = "10.3390/pharmaceutics14040825"
}
Vekić, J., Zeljković, A., Stefanović, A., Bogavac-Stanojević, N., Ilias, I., Silva-Nunes, J., Pantea Stoian, A., Janez, A.,& Rizzo, M.. (2022). Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL. in Pharmaceutics
MDPI., 14(4).
https://doi.org/10.3390/pharmaceutics14040825
Vekić J, Zeljković A, Stefanović A, Bogavac-Stanojević N, Ilias I, Silva-Nunes J, Pantea Stoian A, Janez A, Rizzo M. Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL. in Pharmaceutics. 2022;14(4).
doi:10.3390/pharmaceutics14040825 .
Vekić, Jelena, Zeljković, Aleksandra, Stefanović, Aleksandra, Bogavac-Stanojević, Nataša, Ilias, Ioannis, Silva-Nunes, José, Pantea Stoian, Anca, Janez, Andrej, Rizzo, Manfredi, "Novel Pharmaceutical and Nutraceutical-Based Approaches for Cardiovascular Diseases Prevention Targeting Atherogenic Small Dense LDL" in Pharmaceutics, 14, no. 4 (2022),
https://doi.org/10.3390/pharmaceutics14040825 . .
1
5
5

Atherosclerosis Development and Progression: The Role of Atherogenic Small, Dense LDL

Vekić, Jelena; Zeljković, Aleksandra; Cicero, Arrigo F. G.; Janez, Andrej; Stoian, Anca Pantea; Sonmez, Alper; Rizzo, Manfredi

(MDPI, 2022)

TY  - JOUR
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Cicero, Arrigo F. G.
AU  - Janez, Andrej
AU  - Stoian, Anca Pantea
AU  - Sonmez, Alper
AU  - Rizzo, Manfredi
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4063
AB  - Atherosclerosis is responsible for large cardiovascular mortality in many countries globally. It has been shown over the last decades that the reduction of atherosclerotic progression is a critical factor for preventing future cardiovascular events. Low-density lipoproteins (LDL) have been successfully targeted, and their reduction is one of the key preventing measures in patients with atherosclerotic disease. LDL particles are pivotal for the formation and progression of atherosclerotic plaques; yet, they are quite heterogeneous, and smaller, denser LDL species are the most atherogenic. These particles have greater arterial entry and retention, higher susceptibility to oxidation, as well as reduced affinity for the LDL receptor. Increased proportion of small, dense LDL particles is an integral part of the atherogenic lipoprotein phenotype, the most common form of dyslipidemia associated with insulin resistance. Recent data suggest that both genetic and epigenetic factors might induce expression of this specific lipid pattern. In addition, a typical finding of increased small, dense LDL particles was confirmed in different categories of patients with elevated cardiovascular risk. Small, dense LDL is an independent risk factor for cardiovascular diseases, which emphasizes the clinical importance of both the quality and the quantity of LDL. An effective management of atherosclerotic disease should take into account the presence of small, dense LDL in order to prevent cardiovascular complications.
PB  - MDPI
T2  - Medicina
T1  - Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL
VL  - 58
IS  - 2
SP  - 299
DO  - 10.3390/medicina58020299
ER  - 
@article{
author = "Vekić, Jelena and Zeljković, Aleksandra and Cicero, Arrigo F. G. and Janez, Andrej and Stoian, Anca Pantea and Sonmez, Alper and Rizzo, Manfredi",
year = "2022",
abstract = "Atherosclerosis is responsible for large cardiovascular mortality in many countries globally. It has been shown over the last decades that the reduction of atherosclerotic progression is a critical factor for preventing future cardiovascular events. Low-density lipoproteins (LDL) have been successfully targeted, and their reduction is one of the key preventing measures in patients with atherosclerotic disease. LDL particles are pivotal for the formation and progression of atherosclerotic plaques; yet, they are quite heterogeneous, and smaller, denser LDL species are the most atherogenic. These particles have greater arterial entry and retention, higher susceptibility to oxidation, as well as reduced affinity for the LDL receptor. Increased proportion of small, dense LDL particles is an integral part of the atherogenic lipoprotein phenotype, the most common form of dyslipidemia associated with insulin resistance. Recent data suggest that both genetic and epigenetic factors might induce expression of this specific lipid pattern. In addition, a typical finding of increased small, dense LDL particles was confirmed in different categories of patients with elevated cardiovascular risk. Small, dense LDL is an independent risk factor for cardiovascular diseases, which emphasizes the clinical importance of both the quality and the quantity of LDL. An effective management of atherosclerotic disease should take into account the presence of small, dense LDL in order to prevent cardiovascular complications.",
publisher = "MDPI",
journal = "Medicina",
title = "Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL",
volume = "58",
number = "2",
pages = "299",
doi = "10.3390/medicina58020299"
}
Vekić, J., Zeljković, A., Cicero, A. F. G., Janez, A., Stoian, A. P., Sonmez, A.,& Rizzo, M.. (2022). Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL. in Medicina
MDPI., 58(2), 299.
https://doi.org/10.3390/medicina58020299
Vekić J, Zeljković A, Cicero AFG, Janez A, Stoian AP, Sonmez A, Rizzo M. Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL. in Medicina. 2022;58(2):299.
doi:10.3390/medicina58020299 .
Vekić, Jelena, Zeljković, Aleksandra, Cicero, Arrigo F. G., Janez, Andrej, Stoian, Anca Pantea, Sonmez, Alper, Rizzo, Manfredi, "Atherosclerosis Development and Progression: The Role of
Atherogenic Small, Dense LDL" in Medicina, 58, no. 2 (2022):299,
https://doi.org/10.3390/medicina58020299 . .
3
36
33

A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies

Vekić, Jelena; Zeljković, Aleksandra; Rasadi, Khalid; Cesur, Mustafa; Silva-Nunes, José; Pantea Stoian, Anca; Rizzo, Manfredi

(MDPI, 2022)

TY  - JOUR
AU  - Vekić, Jelena
AU  - Zeljković, Aleksandra
AU  - Rasadi, Khalid
AU  - Cesur, Mustafa
AU  - Silva-Nunes, José
AU  - Pantea Stoian, Anca
AU  - Rizzo, Manfredi
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4054
AB  - The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical practice; indeed, despite optimal management and treatment, a considerable proportion of patients still undergo major CV events. Novel lipoprotein biomarkers are suggested as possible targets for improving the outcomes of patients at higher risk for CVD, and their impact on major CV events and mortality have previously been investigated. Innovative antidiabetic therapies have recently shown a significant reduction in atherogenic lipoproteins, beyond their effects on glucose parameters; it has also been suggested that such anti-atherogenic effect may represent a valuable mechanistic explanation for the cardiovascular benefit of, at least, some of the novel antidiabetic agents, such as glucagon-like peptide-1 receptor agonists. This emphasizes the need for further research in the field in order to clearly assess the effects of innovative treatments on different novel biomarkers, including atherogenic lipoproteins, such as small dense low-density lipoprotein (LDL), lipoprotein(a) (Lp(a)) and dysfunctional high-density lipoprotein (HDL). The current article discusses the clinical importance of novel lipid biomarkers for better management of patients in order to overcome residual cardiovascular risk.
PB  - MDPI
T2  - Metabolites
T1  - A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies
VL  - 12
IS  - 2
DO  - 10.3390/metabo12020108
ER  - 
@article{
author = "Vekić, Jelena and Zeljković, Aleksandra and Rasadi, Khalid and Cesur, Mustafa and Silva-Nunes, José and Pantea Stoian, Anca and Rizzo, Manfredi",
year = "2022",
abstract = "The presence of residual cardiovascular disease (CVD) risk is a current dilemma in clinical practice; indeed, despite optimal management and treatment, a considerable proportion of patients still undergo major CV events. Novel lipoprotein biomarkers are suggested as possible targets for improving the outcomes of patients at higher risk for CVD, and their impact on major CV events and mortality have previously been investigated. Innovative antidiabetic therapies have recently shown a significant reduction in atherogenic lipoproteins, beyond their effects on glucose parameters; it has also been suggested that such anti-atherogenic effect may represent a valuable mechanistic explanation for the cardiovascular benefit of, at least, some of the novel antidiabetic agents, such as glucagon-like peptide-1 receptor agonists. This emphasizes the need for further research in the field in order to clearly assess the effects of innovative treatments on different novel biomarkers, including atherogenic lipoproteins, such as small dense low-density lipoprotein (LDL), lipoprotein(a) (Lp(a)) and dysfunctional high-density lipoprotein (HDL). The current article discusses the clinical importance of novel lipid biomarkers for better management of patients in order to overcome residual cardiovascular risk.",
publisher = "MDPI",
journal = "Metabolites",
title = "A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies",
volume = "12",
number = "2",
doi = "10.3390/metabo12020108"
}
Vekić, J., Zeljković, A., Rasadi, K., Cesur, M., Silva-Nunes, J., Pantea Stoian, A.,& Rizzo, M.. (2022). A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies. in Metabolites
MDPI., 12(2).
https://doi.org/10.3390/metabo12020108
Vekić J, Zeljković A, Rasadi K, Cesur M, Silva-Nunes J, Pantea Stoian A, Rizzo M. A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies. in Metabolites. 2022;12(2).
doi:10.3390/metabo12020108 .
Vekić, Jelena, Zeljković, Aleksandra, Rasadi, Khalid, Cesur, Mustafa, Silva-Nunes, José, Pantea Stoian, Anca, Rizzo, Manfredi, "A New Look at Novel Cardiovascular Risk Biomarkers: The Role of Atherogenic Lipoproteins and Innovative Antidiabetic Therapies" in Metabolites, 12, no. 2 (2022),
https://doi.org/10.3390/metabo12020108 . .
2
26
22

Overweight and Obesity in Polycystic Ovary Syndrome: Association with Inflammation, Oxidative Stress and Dyslipidemia

Perović-Blagojević, Iva; Vekić, Jelena; Macut, Đuro; Ignjatović, Svetlana; Miljković-Trailović, Milica; Zeljković, Aleksandra; Spasojević-Kalimanovska, Vesna; Božić-Antić, Ivana; Bjekić-Macut, Jelica; Kastratović-Kotlica, Biljana; Andrić, Zoran; Ilić, Dušan; Kotur-Stevuljević, Jelena

(Cambridge University Press, 2022)

TY  - JOUR
AU  - Perović-Blagojević, Iva
AU  - Vekić, Jelena
AU  - Macut, Đuro
AU  - Ignjatović, Svetlana
AU  - Miljković-Trailović, Milica
AU  - Zeljković, Aleksandra
AU  - Spasojević-Kalimanovska, Vesna
AU  - Božić-Antić, Ivana
AU  - Bjekić-Macut, Jelica
AU  - Kastratović-Kotlica, Biljana
AU  - Andrić, Zoran
AU  - Ilić, Dušan
AU  - Kotur-Stevuljević, Jelena
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3976
AB  - Objective: Polycystic ovary syndrome (PCOS) is associated with altered lipid profile and increased small, dense LDL particles (sdLDL). Considering that paraoxonase 1 (PON1) is an anti-oxidative enzyme located on high-density lipoprotein (HDL) particles, the aim of this study was to investigate the connection between oxidative stress (OS) and PON1 activity with lipoprotein subclasses in PCOS depending on obesity. Methods: In 115 PCOS patients lipoprotein subclasses distributions were determined by gradient gel electrophoresis. OS status was assessed by total oxidative status (TOS), advanced oxidation protein products (AOPP), malondialdehyde (MDA), prooxidant-Antioxidant balance (PAB), total antioxidant status (TAS) and superoxide dismutase (SOD) and PON1 activity. Results: Overweight/obese PCOS patients (n=55) had increased OS compared to normal weight patients (n=60). In addition, overweight/obese group had lower HDL size and higher proportion of HDL 3a subclasses (P<0.05). PAB was in negative correlation with HDL 2a (P<0.001), whereas MDA and SOD correlated positively with HDL 3 subclasses (P<0.05). Serum PON1 activity was positively associated with proportions of PON1 activity on HDL 2b (P<0.05) and 2a (P<0.01), but negatively with the proportion on HDL 3 particles (P<0.01). LDL B phenotype patients had increased TAS, SOD and PON1 activity on HDL 2b, but decreased PON1 activity on HDL 3 subclasses. Conclusion: OS is associated with altered lipoprotein subclasses distribution in PCOS patients. Obesity in PCOS affects the profile of HDL subclasses, reflected through the reduced proportion of PON1 activity on HDL 3 subclasses in the presence of sdLDL particles.
PB  - Cambridge University Press
T2  - British Journal of Nutrition
T1  - Overweight and Obesity in Polycystic Ovary Syndrome: Association with Inflammation, Oxidative Stress and Dyslipidemia
VL  - 128
IS  - 4
SP  - 604
EP  - 612
DO  - 10.1017/S0007114521003585
ER  - 
@article{
author = "Perović-Blagojević, Iva and Vekić, Jelena and Macut, Đuro and Ignjatović, Svetlana and Miljković-Trailović, Milica and Zeljković, Aleksandra and Spasojević-Kalimanovska, Vesna and Božić-Antić, Ivana and Bjekić-Macut, Jelica and Kastratović-Kotlica, Biljana and Andrić, Zoran and Ilić, Dušan and Kotur-Stevuljević, Jelena",
year = "2022",
abstract = "Objective: Polycystic ovary syndrome (PCOS) is associated with altered lipid profile and increased small, dense LDL particles (sdLDL). Considering that paraoxonase 1 (PON1) is an anti-oxidative enzyme located on high-density lipoprotein (HDL) particles, the aim of this study was to investigate the connection between oxidative stress (OS) and PON1 activity with lipoprotein subclasses in PCOS depending on obesity. Methods: In 115 PCOS patients lipoprotein subclasses distributions were determined by gradient gel electrophoresis. OS status was assessed by total oxidative status (TOS), advanced oxidation protein products (AOPP), malondialdehyde (MDA), prooxidant-Antioxidant balance (PAB), total antioxidant status (TAS) and superoxide dismutase (SOD) and PON1 activity. Results: Overweight/obese PCOS patients (n=55) had increased OS compared to normal weight patients (n=60). In addition, overweight/obese group had lower HDL size and higher proportion of HDL 3a subclasses (P<0.05). PAB was in negative correlation with HDL 2a (P<0.001), whereas MDA and SOD correlated positively with HDL 3 subclasses (P<0.05). Serum PON1 activity was positively associated with proportions of PON1 activity on HDL 2b (P<0.05) and 2a (P<0.01), but negatively with the proportion on HDL 3 particles (P<0.01). LDL B phenotype patients had increased TAS, SOD and PON1 activity on HDL 2b, but decreased PON1 activity on HDL 3 subclasses. Conclusion: OS is associated with altered lipoprotein subclasses distribution in PCOS patients. Obesity in PCOS affects the profile of HDL subclasses, reflected through the reduced proportion of PON1 activity on HDL 3 subclasses in the presence of sdLDL particles.",
publisher = "Cambridge University Press",
journal = "British Journal of Nutrition",
title = "Overweight and Obesity in Polycystic Ovary Syndrome: Association with Inflammation, Oxidative Stress and Dyslipidemia",
volume = "128",
number = "4",
pages = "604-612",
doi = "10.1017/S0007114521003585"
}
Perović-Blagojević, I., Vekić, J., Macut, Đ., Ignjatović, S., Miljković-Trailović, M., Zeljković, A., Spasojević-Kalimanovska, V., Božić-Antić, I., Bjekić-Macut, J., Kastratović-Kotlica, B., Andrić, Z., Ilić, D.,& Kotur-Stevuljević, J.. (2022). Overweight and Obesity in Polycystic Ovary Syndrome: Association with Inflammation, Oxidative Stress and Dyslipidemia. in British Journal of Nutrition
Cambridge University Press., 128(4), 604-612.
https://doi.org/10.1017/S0007114521003585
Perović-Blagojević I, Vekić J, Macut Đ, Ignjatović S, Miljković-Trailović M, Zeljković A, Spasojević-Kalimanovska V, Božić-Antić I, Bjekić-Macut J, Kastratović-Kotlica B, Andrić Z, Ilić D, Kotur-Stevuljević J. Overweight and Obesity in Polycystic Ovary Syndrome: Association with Inflammation, Oxidative Stress and Dyslipidemia. in British Journal of Nutrition. 2022;128(4):604-612.
doi:10.1017/S0007114521003585 .
Perović-Blagojević, Iva, Vekić, Jelena, Macut, Đuro, Ignjatović, Svetlana, Miljković-Trailović, Milica, Zeljković, Aleksandra, Spasojević-Kalimanovska, Vesna, Božić-Antić, Ivana, Bjekić-Macut, Jelica, Kastratović-Kotlica, Biljana, Andrić, Zoran, Ilić, Dušan, Kotur-Stevuljević, Jelena, "Overweight and Obesity in Polycystic Ovary Syndrome: Association with Inflammation, Oxidative Stress and Dyslipidemia" in British Journal of Nutrition, 128, no. 4 (2022):604-612,
https://doi.org/10.1017/S0007114521003585 . .
3
15
1
8

The importance of metabolic health improvement in pregnancy: Project "HDL structure and function research in pregnancy"

Zeljković, Aleksandra; Vekić, Jelena; Ardalić, Daniela; Spasojević-Kalimanovska, Vesna; Ivanišević, Jasmina; Gojković, Tamara; Vladimirov, Sandra; Mihajlović, Marija; Antonić, Tamara; Vujčić, Sanja; Miković, Željko; Stefanović, Aleksandra

(Savez farmaceutskih udruženja Srbije (SFUS), 2022)

TY  - CONF
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Ardalić, Daniela
AU  - Spasojević-Kalimanovska, Vesna
AU  - Ivanišević, Jasmina
AU  - Gojković, Tamara
AU  - Vladimirov, Sandra
AU  - Mihajlović, Marija
AU  - Antonić, Tamara
AU  - Vujčić, Sanja
AU  - Miković, Željko
AU  - Stefanović, Aleksandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4487
AB  - Insulin resistance, hyperlipidemia, oxidative stress and low-grade inflammation are
mechanisms underlying endothelial dysfunction and atherosclerosis development in non-
pregnant state, but in pregnancy they are adaptive mechanisms responsible for fetal
development without health risks for mothers. A special feature of lipids profile in pregnancy
is increase in high density lipoprotein (HDL) cholesterol concentration. Protective role of
HDL particles resides on its complex composition that goes beyond its cholesterol
concentration and exhibits vasodilatory, antioxidant, anti-inflammatory and
antithrombogenic effects. Even the importance of HDL functionality in pathogenesis of
cardiovascular disease has been investigated and confirmed its role in persevering metabolic
health in pregnancy are almost unexplored. Project "HDL research to improve pregnancy
outcome" investigate the pattern of HDL particle distribution and functionality (HDL-ome)
with different pregnancy outcomes. With the sophisticated analytical methods we determine
HDL-ome in uncomplicated and high-risk pregnancies. We mark the HDL-ome component
with a different pattern of change during high-risk pregnancies and test their potential for
pregnancy complications risk assessment. In this this research we investigate molecular
mechanisms crucial for HDL remodelling during pregnancy and possible associations
between maternal metabolic health during pregnancy and maternal and child health in the
future. Such comprehensive approach will provide a better insight into HDL role in maternal
metabolic health during pregnancy and will open a door for further research in this area.
AB  - Insulinska rezistencija, hiperlipidemija, oksidativni stress i stanje inflamacije niskog
stepena, koji se u negravidnom stanju povezuju sa razvojem endotelne disfunkcije i
aterosklerozom, u trudnoći predstavljaju adaptivne mehanizme koji omogućavaju pravilan
rast i razvoj fetusa, a ne ugrožavaju zdravlje trudnice. Specifičnost dislipidemije koja se
razvija u trudnoći, a koja nije karakteristična za dislipidemiju u negravidnim stanjima, jeste
porast koncentracije holesterola u lipoproteinskim česticama visoke gustine (high density
lipoprotein, HDL). Međutim, HDL je mnogo više od sadržaja holesterola u njemu. Ovaj
lipoprotein ima izuzetno kompleksnu i heterogenu strukturu i ispoljava vazodilatatorne,
antioksidativne, antiinflamatorne i antitrombogene efekte. Iako je gubitak funkcionalnosti
ovog lipoproteina u patogenezi kardiovaskularnih bolesti detaljno ispitan i potvrđen,
njegova uloga u očuvanju metaboličkog zdravlja u trudnoći još uvek nije rasvetljena. Projekat
"Ispitivanje HDL-metaboloma u cilju unapređenja ishoda trudnoće" bavi se istraživanjem
povezanosti obrazaca promena strukture i funkcionalnosti HDL (HDL-om) sa različitim
ishodima trudnoće. Sofisticiranim analitičkim metodama, određuje se HDL-om u
visokorizičnim trudnoćama, kao i trudnoćama bez komplikacija. Izdvajaju se komponente
HDL-oma koje imaju drugačiji obrazac promene tokom visoko rizičnih trudnoća i ispituje se
njihov značaj u proceni rizika za razvoj komplikacija u trudnoći. Poseban aspekt ovog
istraživanja odnosi se na ispitivanje molekularnih mehanizama ključnih za remodelovanje
HDL tokom trudnoće, kao i potencijalne povezanosti metaboličkog statusa majke tokom
trudnoće sa budućim kardiometaboličkim zdravljem majke i deteta. Ovako opsežno
ispitivanje trebalo bi da pruži jasniji prikaz uloge HDL u očuvanju metaboličkog zdravlja
tokom trudnoće i, kao takvo, predstavljaće polaznu tačku za dalja istraživanja u ovoj oblasti.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - The importance of metabolic health improvement in pregnancy: Project "HDL structure and function research in pregnancy"
T1  - Značaj očuvanja metaboličkog zdravlja u trudnoći: projekat "ispitivanje strukture i funkcije hdl‐a u trudnoći"
VL  - 72
IS  - 4 suplement
SP  - S174
EP  - S175
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4487
ER  - 
@conference{
author = "Zeljković, Aleksandra and Vekić, Jelena and Ardalić, Daniela and Spasojević-Kalimanovska, Vesna and Ivanišević, Jasmina and Gojković, Tamara and Vladimirov, Sandra and Mihajlović, Marija and Antonić, Tamara and Vujčić, Sanja and Miković, Željko and Stefanović, Aleksandra",
year = "2022",
abstract = "Insulin resistance, hyperlipidemia, oxidative stress and low-grade inflammation are
mechanisms underlying endothelial dysfunction and atherosclerosis development in non-
pregnant state, but in pregnancy they are adaptive mechanisms responsible for fetal
development without health risks for mothers. A special feature of lipids profile in pregnancy
is increase in high density lipoprotein (HDL) cholesterol concentration. Protective role of
HDL particles resides on its complex composition that goes beyond its cholesterol
concentration and exhibits vasodilatory, antioxidant, anti-inflammatory and
antithrombogenic effects. Even the importance of HDL functionality in pathogenesis of
cardiovascular disease has been investigated and confirmed its role in persevering metabolic
health in pregnancy are almost unexplored. Project "HDL research to improve pregnancy
outcome" investigate the pattern of HDL particle distribution and functionality (HDL-ome)
with different pregnancy outcomes. With the sophisticated analytical methods we determine
HDL-ome in uncomplicated and high-risk pregnancies. We mark the HDL-ome component
with a different pattern of change during high-risk pregnancies and test their potential for
pregnancy complications risk assessment. In this this research we investigate molecular
mechanisms crucial for HDL remodelling during pregnancy and possible associations
between maternal metabolic health during pregnancy and maternal and child health in the
future. Such comprehensive approach will provide a better insight into HDL role in maternal
metabolic health during pregnancy and will open a door for further research in this area., Insulinska rezistencija, hiperlipidemija, oksidativni stress i stanje inflamacije niskog
stepena, koji se u negravidnom stanju povezuju sa razvojem endotelne disfunkcije i
aterosklerozom, u trudnoći predstavljaju adaptivne mehanizme koji omogućavaju pravilan
rast i razvoj fetusa, a ne ugrožavaju zdravlje trudnice. Specifičnost dislipidemije koja se
razvija u trudnoći, a koja nije karakteristična za dislipidemiju u negravidnim stanjima, jeste
porast koncentracije holesterola u lipoproteinskim česticama visoke gustine (high density
lipoprotein, HDL). Međutim, HDL je mnogo više od sadržaja holesterola u njemu. Ovaj
lipoprotein ima izuzetno kompleksnu i heterogenu strukturu i ispoljava vazodilatatorne,
antioksidativne, antiinflamatorne i antitrombogene efekte. Iako je gubitak funkcionalnosti
ovog lipoproteina u patogenezi kardiovaskularnih bolesti detaljno ispitan i potvrđen,
njegova uloga u očuvanju metaboličkog zdravlja u trudnoći još uvek nije rasvetljena. Projekat
"Ispitivanje HDL-metaboloma u cilju unapređenja ishoda trudnoće" bavi se istraživanjem
povezanosti obrazaca promena strukture i funkcionalnosti HDL (HDL-om) sa različitim
ishodima trudnoće. Sofisticiranim analitičkim metodama, određuje se HDL-om u
visokorizičnim trudnoćama, kao i trudnoćama bez komplikacija. Izdvajaju se komponente
HDL-oma koje imaju drugačiji obrazac promene tokom visoko rizičnih trudnoća i ispituje se
njihov značaj u proceni rizika za razvoj komplikacija u trudnoći. Poseban aspekt ovog
istraživanja odnosi se na ispitivanje molekularnih mehanizama ključnih za remodelovanje
HDL tokom trudnoće, kao i potencijalne povezanosti metaboličkog statusa majke tokom
trudnoće sa budućim kardiometaboličkim zdravljem majke i deteta. Ovako opsežno
ispitivanje trebalo bi da pruži jasniji prikaz uloge HDL u očuvanju metaboličkog zdravlja
tokom trudnoće i, kao takvo, predstavljaće polaznu tačku za dalja istraživanja u ovoj oblasti.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "The importance of metabolic health improvement in pregnancy: Project "HDL structure and function research in pregnancy", Značaj očuvanja metaboličkog zdravlja u trudnoći: projekat "ispitivanje strukture i funkcije hdl‐a u trudnoći"",
volume = "72",
number = "4 suplement",
pages = "S174-S175",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4487"
}
Zeljković, A., Vekić, J., Ardalić, D., Spasojević-Kalimanovska, V., Ivanišević, J., Gojković, T., Vladimirov, S., Mihajlović, M., Antonić, T., Vujčić, S., Miković, Ž.,& Stefanović, A.. (2022). The importance of metabolic health improvement in pregnancy: Project "HDL structure and function research in pregnancy". in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S174-S175.
https://hdl.handle.net/21.15107/rcub_farfar_4487
Zeljković A, Vekić J, Ardalić D, Spasojević-Kalimanovska V, Ivanišević J, Gojković T, Vladimirov S, Mihajlović M, Antonić T, Vujčić S, Miković Ž, Stefanović A. The importance of metabolic health improvement in pregnancy: Project "HDL structure and function research in pregnancy". in Arhiv za farmaciju. 2022;72(4 suplement):S174-S175.
https://hdl.handle.net/21.15107/rcub_farfar_4487 .
Zeljković, Aleksandra, Vekić, Jelena, Ardalić, Daniela, Spasojević-Kalimanovska, Vesna, Ivanišević, Jasmina, Gojković, Tamara, Vladimirov, Sandra, Mihajlović, Marija, Antonić, Tamara, Vujčić, Sanja, Miković, Željko, Stefanović, Aleksandra, "The importance of metabolic health improvement in pregnancy: Project "HDL structure and function research in pregnancy"" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S174-S175,
https://hdl.handle.net/21.15107/rcub_farfar_4487 .

The importance of advanced glycation end products, lipid and redox biomarkers determination in patients with diabetes mellitus

Vujčić, Sanja; Kotur-Stevuljević, Jelena; Beljić Živković, Teodora; Mišić, Milan; Mihajlović, Marija; Erceg, Sanja; Zeljković, Aleksandra; Koprivica‐Uzelac, Branka; Perović‐Blagojević, Iva; Vekić, Jelena

(Savez farmaceutskih udruženja Srbije (SFUS), 2022)

TY  - CONF
AU  - Vujčić, Sanja
AU  - Kotur-Stevuljević, Jelena
AU  - Beljić Živković, Teodora
AU  - Mišić, Milan
AU  - Mihajlović, Marija
AU  - Erceg, Sanja
AU  - Zeljković, Aleksandra
AU  - Koprivica‐Uzelac, Branka
AU  - Perović‐Blagojević, Iva
AU  - Vekić, Jelena
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4509
AB  - Non-enzymatic glycation, oxidative stress (OS) and dyslipidemia are the main
metabolic alterations behind the development of macrovascular
complications (cardiovascular diseases) of diabetes mellitus (DM).
However, clinical relevance of biomarkers of these processes in patients with microvascular
complications (nephropathy, neuropathy, retinopathy) is less understood. Therefore, the aim
of this study was to examine advanced glycation products (AGEs), biomarkers of OS, and
dyslipidemia in 100 DM patients (33 without microvascular complications and 77 with
complications) and 30 subjects without DM. AGEs levels were higher in patients with
complications than in those without complications (median: 5.72; interquartile range: 4.60-
6.54 U/mL vs. median: 4.84; interquartile range: 4.10-5.40 U/L; P<0.05). In addition to
AGEs, the group with diabetic retinopathy had higher plasma total antioxidant capacity
(P<0.05), while the group with diabetic nephropathy had smaller LDL size than the patients
without these complications (25.48±1.26 nm vs. 26.21±1.19 nm; P<0.05). The patients
with co-existing cardiovascular disease were further characterized by dysfunctional HDL
particles, as evidenced by increased small HDL particles (P<0.05) and reduced paraoxonase-
1 activities. Significant increase in both pro-oxidant-antioxidant balance and ischemia-
modified albumin (P<0.05), with simultaneously decreased activity of superoxide-dismutase
(P<0.05) was found in patients with progressive diabetic neuropathy, indicating the highest
degree of oxidative damage. It can be concluded that patients with microvascular
complications of DM have aggravated redox imbalance and lipid profile alterations. In
addition to metabolic control, strategies aimed at lowering OS and correcting dyslipidemia
can contribute to the prevention of microvascular complications of diabetes.
AB  - Neenzimska glikacija, oksidativni stres (OS) i dislipidemija su glavni metabolički
procesi koji dovode do razvoja makrovaskularnih komplikacija (kardiovaskularnih bolesti)
dijabetesa melitusa (DM). Međutim, klinički značaj određivanja biomarkera ovih procesa
kod pacijenata sa mikrovaskularnim komplikacijama (retinopatija, nefropatija, neuropatija)
nije dovoljno razjašnjen. Cilj ovog istraživanja je bio ispitivanje produkata uznapredovale
glikacije (AGE), biomarkera OS i dislipidemije kod 100 pacijenata sa DM (33 bez
mikrovaskularnih komplikacija i 77 sa komplikacijama) i 30 ispitanika bez DM. Nivo
cirkulišućih AGE je bio značajno viši u grupi pacijenata sa komplikacijama (medijana: 5,72;
interkvartilni raspon: 4,60-6,54 U/mL) u odnosu na pacijente bez komplikacija (medijana:
4,84; interkvartilni raspon 4,10-5,40 U/L; P<0,05). Pored povišenih koncentracija AGE,
pacijenti sa dijabetesnom retinopatijom su imali i povišene vrednosti totalnog oksidativnog
statusa (P<0,05), a pacijenti sa dijabetesnom nefropatijom manje dijametre LDL čestica
(25,48±1,26 nm) u poređenju sa sa pacijentima bez komplikacija (26,21±1,19 nm;
P<0,05). Nadalje, kod pacijenata sa pridruženim makrovaskularnim komplikacijama
(kardiovaskularnim bolestima) utvrđeno je prisustvo disfunkcionalnih HDL čestica, na
osnovu povećanog udela malih HDL čestica (P<0.05) i smanjene aktivnosti paroksonaze-
1. Pacijenti sa progresivnom dijabetesnom neuropatijom su imali značajno povišene
vrednosti prooksidativno-antioksidativnog balansa i ishemijom modifikovanog albumina
(P<0,05), uz istovremeno sniženje aktivnosti superoksid-dismutaze (P<0,05), što ukazuje da
je stepen oksidativnog oštećenja u ovoj grupi bio najveći. Može se zaključiti da, pored
adekvatne metaboliče kontrole, strategije usmerene ka sniženju OS i korekciji dislipidemije,
mogu doprineti prevenciji razvoja mikrovaskularnih komplikacija dijabetesa.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - The importance of advanced glycation end products, lipid and redox biomarkers determination in patients with diabetes mellitus
T1  - Značaj određivanja produkata uznapredovale glikacije i biomarkera lipidnog i redoks statusa kod pacijenata sa dijabetes melitusom
VL  - 72
IS  - 4 suplement
SP  - S229
EP  - S230
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4509
ER  - 
@conference{
author = "Vujčić, Sanja and Kotur-Stevuljević, Jelena and Beljić Živković, Teodora and Mišić, Milan and Mihajlović, Marija and Erceg, Sanja and Zeljković, Aleksandra and Koprivica‐Uzelac, Branka and Perović‐Blagojević, Iva and Vekić, Jelena",
year = "2022",
abstract = "Non-enzymatic glycation, oxidative stress (OS) and dyslipidemia are the main
metabolic alterations behind the development of macrovascular
complications (cardiovascular diseases) of diabetes mellitus (DM).
However, clinical relevance of biomarkers of these processes in patients with microvascular
complications (nephropathy, neuropathy, retinopathy) is less understood. Therefore, the aim
of this study was to examine advanced glycation products (AGEs), biomarkers of OS, and
dyslipidemia in 100 DM patients (33 without microvascular complications and 77 with
complications) and 30 subjects without DM. AGEs levels were higher in patients with
complications than in those without complications (median: 5.72; interquartile range: 4.60-
6.54 U/mL vs. median: 4.84; interquartile range: 4.10-5.40 U/L; P<0.05). In addition to
AGEs, the group with diabetic retinopathy had higher plasma total antioxidant capacity
(P<0.05), while the group with diabetic nephropathy had smaller LDL size than the patients
without these complications (25.48±1.26 nm vs. 26.21±1.19 nm; P<0.05). The patients
with co-existing cardiovascular disease were further characterized by dysfunctional HDL
particles, as evidenced by increased small HDL particles (P<0.05) and reduced paraoxonase-
1 activities. Significant increase in both pro-oxidant-antioxidant balance and ischemia-
modified albumin (P<0.05), with simultaneously decreased activity of superoxide-dismutase
(P<0.05) was found in patients with progressive diabetic neuropathy, indicating the highest
degree of oxidative damage. It can be concluded that patients with microvascular
complications of DM have aggravated redox imbalance and lipid profile alterations. In
addition to metabolic control, strategies aimed at lowering OS and correcting dyslipidemia
can contribute to the prevention of microvascular complications of diabetes., Neenzimska glikacija, oksidativni stres (OS) i dislipidemija su glavni metabolički
procesi koji dovode do razvoja makrovaskularnih komplikacija (kardiovaskularnih bolesti)
dijabetesa melitusa (DM). Međutim, klinički značaj određivanja biomarkera ovih procesa
kod pacijenata sa mikrovaskularnim komplikacijama (retinopatija, nefropatija, neuropatija)
nije dovoljno razjašnjen. Cilj ovog istraživanja je bio ispitivanje produkata uznapredovale
glikacije (AGE), biomarkera OS i dislipidemije kod 100 pacijenata sa DM (33 bez
mikrovaskularnih komplikacija i 77 sa komplikacijama) i 30 ispitanika bez DM. Nivo
cirkulišućih AGE je bio značajno viši u grupi pacijenata sa komplikacijama (medijana: 5,72;
interkvartilni raspon: 4,60-6,54 U/mL) u odnosu na pacijente bez komplikacija (medijana:
4,84; interkvartilni raspon 4,10-5,40 U/L; P<0,05). Pored povišenih koncentracija AGE,
pacijenti sa dijabetesnom retinopatijom su imali i povišene vrednosti totalnog oksidativnog
statusa (P<0,05), a pacijenti sa dijabetesnom nefropatijom manje dijametre LDL čestica
(25,48±1,26 nm) u poređenju sa sa pacijentima bez komplikacija (26,21±1,19 nm;
P<0,05). Nadalje, kod pacijenata sa pridruženim makrovaskularnim komplikacijama
(kardiovaskularnim bolestima) utvrđeno je prisustvo disfunkcionalnih HDL čestica, na
osnovu povećanog udela malih HDL čestica (P<0.05) i smanjene aktivnosti paroksonaze-
1. Pacijenti sa progresivnom dijabetesnom neuropatijom su imali značajno povišene
vrednosti prooksidativno-antioksidativnog balansa i ishemijom modifikovanog albumina
(P<0,05), uz istovremeno sniženje aktivnosti superoksid-dismutaze (P<0,05), što ukazuje da
je stepen oksidativnog oštećenja u ovoj grupi bio najveći. Može se zaključiti da, pored
adekvatne metaboliče kontrole, strategije usmerene ka sniženju OS i korekciji dislipidemije,
mogu doprineti prevenciji razvoja mikrovaskularnih komplikacija dijabetesa.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "The importance of advanced glycation end products, lipid and redox biomarkers determination in patients with diabetes mellitus, Značaj određivanja produkata uznapredovale glikacije i biomarkera lipidnog i redoks statusa kod pacijenata sa dijabetes melitusom",
volume = "72",
number = "4 suplement",
pages = "S229-S230",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4509"
}
Vujčić, S., Kotur-Stevuljević, J., Beljić Živković, T., Mišić, M., Mihajlović, M., Erceg, S., Zeljković, A., Koprivica‐Uzelac, B., Perović‐Blagojević, I.,& Vekić, J.. (2022). The importance of advanced glycation end products, lipid and redox biomarkers determination in patients with diabetes mellitus. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S229-S230.
https://hdl.handle.net/21.15107/rcub_farfar_4509
Vujčić S, Kotur-Stevuljević J, Beljić Živković T, Mišić M, Mihajlović M, Erceg S, Zeljković A, Koprivica‐Uzelac B, Perović‐Blagojević I, Vekić J. The importance of advanced glycation end products, lipid and redox biomarkers determination in patients with diabetes mellitus. in Arhiv za farmaciju. 2022;72(4 suplement):S229-S230.
https://hdl.handle.net/21.15107/rcub_farfar_4509 .
Vujčić, Sanja, Kotur-Stevuljević, Jelena, Beljić Živković, Teodora, Mišić, Milan, Mihajlović, Marija, Erceg, Sanja, Zeljković, Aleksandra, Koprivica‐Uzelac, Branka, Perović‐Blagojević, Iva, Vekić, Jelena, "The importance of advanced glycation end products, lipid and redox biomarkers determination in patients with diabetes mellitus" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S229-S230,
https://hdl.handle.net/21.15107/rcub_farfar_4509 .

Antioxidant properties of HDL: beyond cardiovascular protection

Zeljković, Aleksandra; Vekić, Jelena; Kotur-Stevuljević, Jelena; Stefanović, Aleksandra; Mihajlović, Marija

(Savez farmaceutskih udruženja Srbije (SFUS), 2022)

TY  - CONF
AU  - Zeljković, Aleksandra
AU  - Vekić, Jelena
AU  - Kotur-Stevuljević, Jelena
AU  - Stefanović, Aleksandra
AU  - Mihajlović, Marija
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4481
AB  - High-density lipoprotein (HDL) is the most complex lipoprotein particle, containing
lipids and dozens of various functional proteins. Such sophisticated composition enables
numerous activities of HDL; from the reverse cholesterol transport, to antioxidative, anti-
inflammatory, anti-aggregation, antiadhesive, and vasodilatory effects. Accordingly, the
significance of HDL goes far beyond its cardioprotective properties and novel research
points towards its role in etiopathogenesis of various other diseases. Antioxidative
properties of HDL are primarily attributed to the enzyme paraoxonase 1 (PON1), whose
principal role is to protect low-density lipoprotein (LDL) and cell membranes against
harmful effects of reactive oxygen species (1). PON1 is located on HDL particles and its
activity largely depends on HDL structure. Our investigations have shown that PON1 is not
equally distributed across the entire population of serum HDL subfractions. Namely, our
results suggest that the allocation of PON1 on specific HDL subclasses changes in
pathophysiological conditions, such as chronic kidney disease, polycystic ovary syndrome, or
hypertension in pregnancy. Similarly, a shift in HDL subclasses distribution toward smaller,
dysfunctional particles is reported in diabetes, metabolic syndrome, obstructive sleep apnea,
sarcoidosis, but also in malignant diseases, such as colorectal cancer. In parallel,
antioxidative defense mechanisms were diminished in all these categories of patients, which
was evident as decreased PON1 activity and rise of oxidative stress. Structural modifications
of HDL particles affect their functions, thus antioxidative capability of PON1 depends on
qualitative properties of its lipoprotein carrier. Such complex interaction is highly significant
for the initiation and progression of numerous diseases.
AB  - Lipoprotein visoke gustine (high‐density lipoprotein, HDL) je najkompleksnija
lipoproteinska čestica koja, pored lipidnih komponenti, sadrži i desetine različitih
funkcionalnih proteina. Ovakav složen sastav omogućava brojne funkcije HDL; od reverznog
transporta holesterola, do antioksidativnih, antiinflamatornih, antiagregacijskih,
antiadhezivnih i vazodilatatornih svojstava. U skladu s tim, značaj HDL u mnogome
prevazilazi kardioprotektivne efekte, a savremena otkrića ukazuju na ulogu ovih čestica u
etiopatogenezi različitih oboljenja. Antioksidativna svojstva HDL prevashodno su vezana za
enzim paraoksonazu 1 (PON1), čija je osnovna funkcija zaštita lipoproteina niske gustine
(low‐density lipoprotein, LDL) i ćelijskih membrana od oksidativnih oštećenja (1). PON1 je
locirana na HDL česticama i uočeno je da aktivnost ovog enzima u velikoj meri zavisi od
strukture samog HDL. U našim istraživanjima pokazali smo da PON1 nije ravnomerno
zastupljena na svim subfrakcijama HDL, te da se ova zastupljenost menja u različitim
patofiziološkim stanjima, kao što su hronične bubrežne bolesti, sindrom policističnih jajnika,
ili hipertenzija u trudnoći. Slično tome, pomeranje raspodele HDL subfrakcija ka manjim,
disfunkcionalnim česticama uočeno je kod pedijatrijskih i odraslih pacijenata sa dijabetesom,
metaboličkim sindromom, opstruktivnom apnejom u toku spavanja, sarkoidozom, ali i sa
malignim bolestima, kao što je kolorektalni karcinom. Istovremeno, nivo antioksidativne
zaštite kod ovih pacijenata je bio snižen, što je bilo vidljivo i kao smanjenje aktivnosti PON1,
te sledstveno povećanje nivoa oksidativnog stresa. Strukturne modifikacije HDL čestica utiču
na njihovu funkciju, pa tako i antioksidativni kapacitet enzima PON1 zavisi od kvalitativnih
svojstava njegovog lipoproteinskog nosača. Ovakva složena interakcija između HDL i
pridruženih funkcionalnih proteina značajna je za nastanak i progresiju brojnih oboljenja.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Antioxidant properties of HDL: beyond cardiovascular protection
T1  - Antioksidativna svojstva lipoproteina visoke gustine: više od kardiovaskularne zaštite
VL  - 72
IS  - 4 suplement
SP  - S150
EP  - S151
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4481
ER  - 
@conference{
author = "Zeljković, Aleksandra and Vekić, Jelena and Kotur-Stevuljević, Jelena and Stefanović, Aleksandra and Mihajlović, Marija",
year = "2022",
abstract = "High-density lipoprotein (HDL) is the most complex lipoprotein particle, containing
lipids and dozens of various functional proteins. Such sophisticated composition enables
numerous activities of HDL; from the reverse cholesterol transport, to antioxidative, anti-
inflammatory, anti-aggregation, antiadhesive, and vasodilatory effects. Accordingly, the
significance of HDL goes far beyond its cardioprotective properties and novel research
points towards its role in etiopathogenesis of various other diseases. Antioxidative
properties of HDL are primarily attributed to the enzyme paraoxonase 1 (PON1), whose
principal role is to protect low-density lipoprotein (LDL) and cell membranes against
harmful effects of reactive oxygen species (1). PON1 is located on HDL particles and its
activity largely depends on HDL structure. Our investigations have shown that PON1 is not
equally distributed across the entire population of serum HDL subfractions. Namely, our
results suggest that the allocation of PON1 on specific HDL subclasses changes in
pathophysiological conditions, such as chronic kidney disease, polycystic ovary syndrome, or
hypertension in pregnancy. Similarly, a shift in HDL subclasses distribution toward smaller,
dysfunctional particles is reported in diabetes, metabolic syndrome, obstructive sleep apnea,
sarcoidosis, but also in malignant diseases, such as colorectal cancer. In parallel,
antioxidative defense mechanisms were diminished in all these categories of patients, which
was evident as decreased PON1 activity and rise of oxidative stress. Structural modifications
of HDL particles affect their functions, thus antioxidative capability of PON1 depends on
qualitative properties of its lipoprotein carrier. Such complex interaction is highly significant
for the initiation and progression of numerous diseases., Lipoprotein visoke gustine (high‐density lipoprotein, HDL) je najkompleksnija
lipoproteinska čestica koja, pored lipidnih komponenti, sadrži i desetine različitih
funkcionalnih proteina. Ovakav složen sastav omogućava brojne funkcije HDL; od reverznog
transporta holesterola, do antioksidativnih, antiinflamatornih, antiagregacijskih,
antiadhezivnih i vazodilatatornih svojstava. U skladu s tim, značaj HDL u mnogome
prevazilazi kardioprotektivne efekte, a savremena otkrića ukazuju na ulogu ovih čestica u
etiopatogenezi različitih oboljenja. Antioksidativna svojstva HDL prevashodno su vezana za
enzim paraoksonazu 1 (PON1), čija je osnovna funkcija zaštita lipoproteina niske gustine
(low‐density lipoprotein, LDL) i ćelijskih membrana od oksidativnih oštećenja (1). PON1 je
locirana na HDL česticama i uočeno je da aktivnost ovog enzima u velikoj meri zavisi od
strukture samog HDL. U našim istraživanjima pokazali smo da PON1 nije ravnomerno
zastupljena na svim subfrakcijama HDL, te da se ova zastupljenost menja u različitim
patofiziološkim stanjima, kao što su hronične bubrežne bolesti, sindrom policističnih jajnika,
ili hipertenzija u trudnoći. Slično tome, pomeranje raspodele HDL subfrakcija ka manjim,
disfunkcionalnim česticama uočeno je kod pedijatrijskih i odraslih pacijenata sa dijabetesom,
metaboličkim sindromom, opstruktivnom apnejom u toku spavanja, sarkoidozom, ali i sa
malignim bolestima, kao što je kolorektalni karcinom. Istovremeno, nivo antioksidativne
zaštite kod ovih pacijenata je bio snižen, što je bilo vidljivo i kao smanjenje aktivnosti PON1,
te sledstveno povećanje nivoa oksidativnog stresa. Strukturne modifikacije HDL čestica utiču
na njihovu funkciju, pa tako i antioksidativni kapacitet enzima PON1 zavisi od kvalitativnih
svojstava njegovog lipoproteinskog nosača. Ovakva složena interakcija između HDL i
pridruženih funkcionalnih proteina značajna je za nastanak i progresiju brojnih oboljenja.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Antioxidant properties of HDL: beyond cardiovascular protection, Antioksidativna svojstva lipoproteina visoke gustine: više od kardiovaskularne zaštite",
volume = "72",
number = "4 suplement",
pages = "S150-S151",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4481"
}
Zeljković, A., Vekić, J., Kotur-Stevuljević, J., Stefanović, A.,& Mihajlović, M.. (2022). Antioxidant properties of HDL: beyond cardiovascular protection. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S150-S151.
https://hdl.handle.net/21.15107/rcub_farfar_4481
Zeljković A, Vekić J, Kotur-Stevuljević J, Stefanović A, Mihajlović M. Antioxidant properties of HDL: beyond cardiovascular protection. in Arhiv za farmaciju. 2022;72(4 suplement):S150-S151.
https://hdl.handle.net/21.15107/rcub_farfar_4481 .
Zeljković, Aleksandra, Vekić, Jelena, Kotur-Stevuljević, Jelena, Stefanović, Aleksandra, Mihajlović, Marija, "Antioxidant properties of HDL: beyond cardiovascular protection" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S150-S151,
https://hdl.handle.net/21.15107/rcub_farfar_4481 .

Biomarkers of vitamin D status in healthy adults: associations with serum lipid parameters – a pilot study

Zeljković, Aleksandra; Vladimirov, Sandra; Gojković, Tamara; Vekić, Jelena; Mihajlović, Marija; Spasojević-Kalimanovska, Vesna

(Pharmaceutical Association of Serbia, 2022)

TY  - JOUR
AU  - Zeljković, Aleksandra
AU  - Vladimirov, Sandra
AU  - Gojković, Tamara
AU  - Vekić, Jelena
AU  - Mihajlović, Marija
AU  - Spasojević-Kalimanovska, Vesna
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4243
AB  - Vitamin D deficiency is among important healthcare challenges today. Traditionally, vitamin D status is assessed through determination of 25-hydroxy metabolite (25(OH)D), but novel data point to 24,25(OH) 2 D and 25(OH)D/24,25(OH) 2 D ratio (VDMR) as promising biomarkers. It is widely accepted that the biological role of vitamin D exceeds its well-known contribution to bone turnover. However, its effects on overall energy metabolism and lipid status alterations are not completely understood. In this study, we analyzed the relationship of vitamin D status assessed as concentrations of 25(OH)D3 and 24,25(OH) 2 D3 determined by liquid chromatography-tandem mass spectrometry, as well as VDMR with advanced lipid status parameters. Vitamin D status biomarkers, routine parameters of lipid status and size and distribution of lipoprotein subclasses were determined in 89 healthy adults (35 with adequate vitamin D status and 54 with vitamin D deficiency). Our results indicated a preponderance of pro- atherogenic small, dense LDL particles (sdLDL) in vitamin D deficient subjects. Both 25(OH)D and 24,25(OH) 2 D were associated with a relative proportion of sdLDL (B: -0.410; SE: 0.154; P=0.010; and B: -2.041; SE: 0.969; P=0.039, respectively). Positive correlation was found for VDMR and relative proportion of HDL 3a particles (ρ=0.251; P=0.024). VDMR value was decreased in subjects with vitamin D deficiency (P=0.001), thus implying its usefulness as a biomarker. A thorough investigation of novel vitamin D biomarkers and advanced lipid status parameters can be useful in the estimation of individual risk for the development of cardiometabolic alterations.
AB  - Deficijencija vitamina D je jedan od značajnih izazova za zdravstvene sisteme današnjice. Tradicionalno, status vitamina D se procenjuje na osnovu određivanja koncentracije njegovog 25- hidroksi metabolita (25(OH)D), ali novi podaci ukazuju na potencijalni značaj 24,25(OH) 2D i odnosa 25(OH)D/24,25(OH) 2 D (VDMR). Danas je široko prihvaćeno da biološka uloga vitamina D uveliko prevazilazi njegove efekte na koštani promet. Međutim, još uvek nije u potpunosti jasan uticaj vitamina D na energetski metabolizam i izmene lipidnog statusa. U ovom istraživanju ispitivali smo povezanost između statusa vitamina D, procenjenog na osnovu nivoa 25(OH)D3 i 24,25(OH) 2 D3 koji su određeni metodom tečne hromatografije – tandem masene spektrometrije, te VDMR sa standardnim i novim parametrima lipidnog statusa. Ispitivani analiti određeni su kod 89 zdravih odraslih osoba. Naši rezultati ukazuju na povećan udeo malih gustih LDL čestica (sdLDL) kod osoba sa deficijencijom vitamina D. Koncentracije 25(OH)D i 24,25(OH) 2 D su bile nezavisno povezane sa relativnim udelom sdLDL (B: -0,410; SE: 0,154; P=0,010; i B: -2,041; SE: 0,969; P=0,039, redom). Uočena je pozitivna korelacija između VDMR i relativnog udela HDL 3a (ρ=0,251; P=0,024). VDMR je snižen kod osoba sa deficijencijom vitamina D (P=0,001), što implicira njegov značaj kao potencijalnog biomarkera. Detaljno ispitivanje novih biomarkera statusa vitamina D i parametara lipidnog profila može biti korisno u proceni individualnog rizika za razvoj kardiometaboličkih poremećaja.
PB  - Pharmaceutical Association of Serbia
T2  - Arhiv za farmaciju
T1  - Biomarkers of vitamin D status in healthy adults: associations with serum lipid parameters – a pilot study
T1  - 273 Biomarkeri statusa vitamina D kod zdravih odraslih osoba: povezanost sa serumskim lipidnim parametrima – pilot studija
VL  - 72
IS  - 2
SP  - 260
EP  - 273
DO  - 10.5937/arhfarm72-36020
ER  - 
@article{
author = "Zeljković, Aleksandra and Vladimirov, Sandra and Gojković, Tamara and Vekić, Jelena and Mihajlović, Marija and Spasojević-Kalimanovska, Vesna",
year = "2022",
abstract = "Vitamin D deficiency is among important healthcare challenges today. Traditionally, vitamin D status is assessed through determination of 25-hydroxy metabolite (25(OH)D), but novel data point to 24,25(OH) 2 D and 25(OH)D/24,25(OH) 2 D ratio (VDMR) as promising biomarkers. It is widely accepted that the biological role of vitamin D exceeds its well-known contribution to bone turnover. However, its effects on overall energy metabolism and lipid status alterations are not completely understood. In this study, we analyzed the relationship of vitamin D status assessed as concentrations of 25(OH)D3 and 24,25(OH) 2 D3 determined by liquid chromatography-tandem mass spectrometry, as well as VDMR with advanced lipid status parameters. Vitamin D status biomarkers, routine parameters of lipid status and size and distribution of lipoprotein subclasses were determined in 89 healthy adults (35 with adequate vitamin D status and 54 with vitamin D deficiency). Our results indicated a preponderance of pro- atherogenic small, dense LDL particles (sdLDL) in vitamin D deficient subjects. Both 25(OH)D and 24,25(OH) 2 D were associated with a relative proportion of sdLDL (B: -0.410; SE: 0.154; P=0.010; and B: -2.041; SE: 0.969; P=0.039, respectively). Positive correlation was found for VDMR and relative proportion of HDL 3a particles (ρ=0.251; P=0.024). VDMR value was decreased in subjects with vitamin D deficiency (P=0.001), thus implying its usefulness as a biomarker. A thorough investigation of novel vitamin D biomarkers and advanced lipid status parameters can be useful in the estimation of individual risk for the development of cardiometabolic alterations., Deficijencija vitamina D je jedan od značajnih izazova za zdravstvene sisteme današnjice. Tradicionalno, status vitamina D se procenjuje na osnovu određivanja koncentracije njegovog 25- hidroksi metabolita (25(OH)D), ali novi podaci ukazuju na potencijalni značaj 24,25(OH) 2D i odnosa 25(OH)D/24,25(OH) 2 D (VDMR). Danas je široko prihvaćeno da biološka uloga vitamina D uveliko prevazilazi njegove efekte na koštani promet. Međutim, još uvek nije u potpunosti jasan uticaj vitamina D na energetski metabolizam i izmene lipidnog statusa. U ovom istraživanju ispitivali smo povezanost između statusa vitamina D, procenjenog na osnovu nivoa 25(OH)D3 i 24,25(OH) 2 D3 koji su određeni metodom tečne hromatografije – tandem masene spektrometrije, te VDMR sa standardnim i novim parametrima lipidnog statusa. Ispitivani analiti određeni su kod 89 zdravih odraslih osoba. Naši rezultati ukazuju na povećan udeo malih gustih LDL čestica (sdLDL) kod osoba sa deficijencijom vitamina D. Koncentracije 25(OH)D i 24,25(OH) 2 D su bile nezavisno povezane sa relativnim udelom sdLDL (B: -0,410; SE: 0,154; P=0,010; i B: -2,041; SE: 0,969; P=0,039, redom). Uočena je pozitivna korelacija između VDMR i relativnog udela HDL 3a (ρ=0,251; P=0,024). VDMR je snižen kod osoba sa deficijencijom vitamina D (P=0,001), što implicira njegov značaj kao potencijalnog biomarkera. Detaljno ispitivanje novih biomarkera statusa vitamina D i parametara lipidnog profila može biti korisno u proceni individualnog rizika za razvoj kardiometaboličkih poremećaja.",
publisher = "Pharmaceutical Association of Serbia",
journal = "Arhiv za farmaciju",
title = "Biomarkers of vitamin D status in healthy adults: associations with serum lipid parameters – a pilot study, 273 Biomarkeri statusa vitamina D kod zdravih odraslih osoba: povezanost sa serumskim lipidnim parametrima – pilot studija",
volume = "72",
number = "2",
pages = "260-273",
doi = "10.5937/arhfarm72-36020"
}
Zeljković, A., Vladimirov, S., Gojković, T., Vekić, J., Mihajlović, M.,& Spasojević-Kalimanovska, V.. (2022). Biomarkers of vitamin D status in healthy adults: associations with serum lipid parameters – a pilot study. in Arhiv za farmaciju
Pharmaceutical Association of Serbia., 72(2), 260-273.
https://doi.org/10.5937/arhfarm72-36020
Zeljković A, Vladimirov S, Gojković T, Vekić J, Mihajlović M, Spasojević-Kalimanovska V. Biomarkers of vitamin D status in healthy adults: associations with serum lipid parameters – a pilot study. in Arhiv za farmaciju. 2022;72(2):260-273.
doi:10.5937/arhfarm72-36020 .
Zeljković, Aleksandra, Vladimirov, Sandra, Gojković, Tamara, Vekić, Jelena, Mihajlović, Marija, Spasojević-Kalimanovska, Vesna, "Biomarkers of vitamin D status in healthy adults: associations with serum lipid parameters – a pilot study" in Arhiv za farmaciju, 72, no. 2 (2022):260-273,
https://doi.org/10.5937/arhfarm72-36020 . .

Biomarkers of dyslipidemia in patients with diabetic foot

Vujčić, Sanja; Stefanović, Tatjana; Zeljković, Aleksandra; Mihajlović, Marija; Vekić, Jelena

(Beograd : Savez farmaceutskih udruženja Srbije, 2022)

TY  - JOUR
AU  - Vujčić, Sanja
AU  - Stefanović, Tatjana
AU  - Zeljković, Aleksandra
AU  - Mihajlović, Marija
AU  - Vekić, Jelena
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4187
AB  - Diabetic foot (DF) is one of the most severe complications of diabetes that significantly
reduces the quality of life and survival of patients. Besides firmly established risk factors, novel
data indicate that alterations in lipid metabolism might also be implicated in the development and
progression of DF. Diabetic dyslipidemia is characterized by the atherogenic triad, consisting of
increased triglycerides (TG), decreased high-density lipoprotein cholesterol (HDL-C) levels and
the presence of small, dense low-density lipoprotein (LDL) particles. Accumulating evidence
suggests that profound hypertriglyceridemia and HDL-C reduction are common findings in
patients with diabetic neuropathy and significantly contribute to an increased risk for DF,
amputation and mortality. Small, dense LDL particles play an important role in the development
of cardiovascular complications of diabetes, but their clinical importance in patients with DF
remains to be established. In this paper, we will discuss the significance of standard and novel
lipid biomarker determination in the assessment of the risk for the development and progression
of DF.
AB  - Dijabetesno stopalo (DS) je hronična komplikacija dijabetesa koja značajno pogoršava kvalitet života pacijenata i doprinosi visokoj stopi smrtnosti. Noviji podaci ukazuju da i poremećaj metabolizma lipida može biti uključen u razvoj i progresiju DS. Dislipidemija u dijabetesu se odlikuje postojanjem tzv. aterogene trijade, koju čine povišena koncentracija triglicerida (TG), snižena koncentracija HDL-holesterola (HDL-h) i prisustvo malih, gustih LDL čestica. U nedavno sprovedenim studijama utvrđeno je da izražena hipertrigliceridemija i snižena koncentracija HDL-h, koje su najčešće prisutne kod pacijenata sa dijabetesnom neuropatijom, dodatno doprinose razvoju DS, amputaciji i mortalitetu. Poznato je da male, guste LDL čestice imaju važnu ulogu u razvoju kardiovaskularnih komplikacija u dijabetesu, ali je značaj ovih čestica kod pacijenata sa DS još uvek nedovoljno ispitan. U ovom radu ćemo razmotriti značaj određivanja standardnih i novih lipidnih biomarkera u cilju procene rizika za razvoj i progresiju DS.
PB  - Beograd : Savez farmaceutskih udruženja Srbije
T2  - Arhiv za farmaciju
T1  - Biomarkers of dyslipidemia in patients with diabetic foot
T1  - Biomarkeri dislipidemije kod pacijenata sa dijabetesnim stopalom
VL  - 72
IS  - 2
SP  - 184
EP  - 192
DO  - 10.5937/arhfarm72-36296
ER  - 
@article{
author = "Vujčić, Sanja and Stefanović, Tatjana and Zeljković, Aleksandra and Mihajlović, Marija and Vekić, Jelena",
year = "2022",
abstract = "Diabetic foot (DF) is one of the most severe complications of diabetes that significantly
reduces the quality of life and survival of patients. Besides firmly established risk factors, novel
data indicate that alterations in lipid metabolism might also be implicated in the development and
progression of DF. Diabetic dyslipidemia is characterized by the atherogenic triad, consisting of
increased triglycerides (TG), decreased high-density lipoprotein cholesterol (HDL-C) levels and
the presence of small, dense low-density lipoprotein (LDL) particles. Accumulating evidence
suggests that profound hypertriglyceridemia and HDL-C reduction are common findings in
patients with diabetic neuropathy and significantly contribute to an increased risk for DF,
amputation and mortality. Small, dense LDL particles play an important role in the development
of cardiovascular complications of diabetes, but their clinical importance in patients with DF
remains to be established. In this paper, we will discuss the significance of standard and novel
lipid biomarker determination in the assessment of the risk for the development and progression
of DF., Dijabetesno stopalo (DS) je hronična komplikacija dijabetesa koja značajno pogoršava kvalitet života pacijenata i doprinosi visokoj stopi smrtnosti. Noviji podaci ukazuju da i poremećaj metabolizma lipida može biti uključen u razvoj i progresiju DS. Dislipidemija u dijabetesu se odlikuje postojanjem tzv. aterogene trijade, koju čine povišena koncentracija triglicerida (TG), snižena koncentracija HDL-holesterola (HDL-h) i prisustvo malih, gustih LDL čestica. U nedavno sprovedenim studijama utvrđeno je da izražena hipertrigliceridemija i snižena koncentracija HDL-h, koje su najčešće prisutne kod pacijenata sa dijabetesnom neuropatijom, dodatno doprinose razvoju DS, amputaciji i mortalitetu. Poznato je da male, guste LDL čestice imaju važnu ulogu u razvoju kardiovaskularnih komplikacija u dijabetesu, ali je značaj ovih čestica kod pacijenata sa DS još uvek nedovoljno ispitan. U ovom radu ćemo razmotriti značaj određivanja standardnih i novih lipidnih biomarkera u cilju procene rizika za razvoj i progresiju DS.",
publisher = "Beograd : Savez farmaceutskih udruženja Srbije",
journal = "Arhiv za farmaciju",
title = "Biomarkers of dyslipidemia in patients with diabetic foot, Biomarkeri dislipidemije kod pacijenata sa dijabetesnim stopalom",
volume = "72",
number = "2",
pages = "184-192",
doi = "10.5937/arhfarm72-36296"
}
Vujčić, S., Stefanović, T., Zeljković, A., Mihajlović, M.,& Vekić, J.. (2022). Biomarkers of dyslipidemia in patients with diabetic foot. in Arhiv za farmaciju
Beograd : Savez farmaceutskih udruženja Srbije., 72(2), 184-192.
https://doi.org/10.5937/arhfarm72-36296
Vujčić S, Stefanović T, Zeljković A, Mihajlović M, Vekić J. Biomarkers of dyslipidemia in patients with diabetic foot. in Arhiv za farmaciju. 2022;72(2):184-192.
doi:10.5937/arhfarm72-36296 .
Vujčić, Sanja, Stefanović, Tatjana, Zeljković, Aleksandra, Mihajlović, Marija, Vekić, Jelena, "Biomarkers of dyslipidemia in patients with diabetic foot" in Arhiv za farmaciju, 72, no. 2 (2022):184-192,
https://doi.org/10.5937/arhfarm72-36296 . .